US006906094B2

(12) **United States Patent**
Barvian et al.

(10) **Patent No.: US 6,906,094 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE**

(75) Inventors: **Nicole Chantel Barvian**, Ann Arbor, MI (US); **Patrick Michael O'Brien**, Stockbridge, MI (US); **William Chester Patt**, Chelsea, MI (US); **Joseph Armand Picard**, Canton, MI (US); **Drago Robert Sliskovic**, Saline, MI (US)

(73) Assignee: **Warner-Lambert Company**, Morris Plains, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 135 days.

(21) Appl. No.: **10/362,104**

(22) PCT Filed: **May 8, 2001**

(86) PCT No.: **PCT/US01/14795**

§ 371 (c)(1),
(2), (4) Date: **Feb. 21, 2003**

(87) PCT Pub. No.: **WO01/96298**

PCT Pub. Date: **Dec. 20, 2001**

(65) **Prior Publication Data**

US 2004/0053983 A1 Mar. 18, 2004

Related U.S. Application Data

(60) Provisional application No. 60/211,498, filed on Jun. 14, 2000.

(51) **Int. Cl.**[7] **A61K 31/404**; C07D 209/04

(52) **U.S. Cl.** **514/415**; 548/490

(58) **Field of Search** 548/490; 514/415

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,595,780	A	6/1986	Ogata et al.	564/79
6,269,387	B1	7/2001	Connor et al.	514/352
2001/0031874	A1	10/2001	Connor et al.	

FOREIGN PATENT DOCUMENTS

DE	4238233	5/1994
EP	0148725	7/1985
WO	9932433	7/1999
WO	0196299	12/2001

Primary Examiner—Golam M M Shameem
(74) *Attorney, Agent, or Firm*—Charles W. Ashbrook; Eric J. Baude; Claude F. Purchase, Jr.

(57) **ABSTRACT**

The present invention provides compounds of formula (I) wherein R, Z, Y, W, R_5, V, and X are as defined in the description, and pharmaceutically acceptable salts thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

(I)



16 Claims, No Drawings

(12) **United States Patent**
Tang et al.

(10) **Patent No.: US 6,906,093 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE**

(75) Inventors: **Peng Cho Tang**, Moraga, CA (US); **Li Sun**, Foster City, CA (US); **Gerald McMahon**, San Francisco, CA (US); **Klaus Peter Hirth**, San Francisco, CA (US); **Laura Kay Shawver**, San Francisco, CA (US)

(73) Assignee: **Sugen, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 25 days.

(21) Appl. No.: **09/897,755**

(22) Filed: **Jul. 3, 2001**

(65) **Prior Publication Data**

US 2002/0102608 A1 Aug. 1, 2002

Related U.S. Application Data

(63) Continuation of application No. 08/702,232, filed on Aug. 23, 1996, now abandoned, which is a continuation-in-part of application No. 08/655,255, filed on Jun. 5, 1996, now abandoned, which is a continuation-in-part of application No. 08/655,226, filed on Jun. 5, 1996, now Pat. No. 5,886,020, which is a continuation-in-part of application No. 08/655,223, filed on Jun. 5, 1996, now Pat. No. 5,792,783, which is a continuation-in-part of application No. 08/655,224, filed on Jun. 5, 1996, now Pat. No. 5,883,116, which is a continuation-in-part of application No. 08/659,191, filed on Jun. 5, 1996, now Pat. No. 5,883,113, which is a continuation-in-part of application No. 08/485,323, filed on Jun. 7, 1995, now Pat. No. 5,880,141.

(51) **Int. Cl.**[7] **A61K 31/40**; C07D 209/02

(52) **U.S. Cl.** **514/414**; 548/468

(58) **Field of Search** 514/414; 548/468

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,872,372	A	2/1959	Hull	
2,968,557	A	1/1961	Burgandt et al.	
4,002,749	A	1/1977	Rovnyak	424/248
4,053,613	A	10/1977	Rovnyak et al.	424/246
4,642,309	A	2/1987	Michel et al.	
4,826,847	A	5/1989	Michel et al.	
4,853,403	A	8/1989	Shimishi et al.	
4,868,304	A	9/1989	Larock et al.	
4,966,849	A	10/1990	Vallee et al.	
4,971,996	A	11/1990	Shiraishi et al.	
5,051,417	A	9/1991	Nadler et al.	
5,057,538	A	10/1991	Shiraishi et al.	
5,089,516	A	2/1992	Shiraishi et al.	
5,124,347	A	6/1992	Connor et al.	
5,196,446	A	3/1993	Levitzki	
5,202,341	A	4/1993	Shiraishi et al.	
5,206,261	A	4/1993	Kawaguchi et al.	
5,217,999	A	6/1993	Levitzki	
5,302,606	A	4/1994	Spada et al.	
5,322,590	A	6/1994	Koshimizu	
5,322,950	A	6/1994	Sircar et al.	
5,330,992	A	7/1994	Eissenstat et al.	
5,374,652	A	12/1994	Buzzetti et al.	
5,382,593	A	1/1995	Le Baut	
5,397,787	A	3/1995	Buzzetti et al.	
5,409,903	A	4/1995	Polak et al.	
5,409,949	A	4/1995	Buzzetti et al.	
5,463,052	A	10/1995	Haga et al.	
5,565,324	A	10/1996	Still et al.	435/6
5,792,783	A *	8/1998	Tang et al.	
5,880,141	A	3/1999	Tang et al.	
5,883,113	A	3/1999	Tang et al.	
5,883,116	A	3/1999	Tang et al.	
5,886,020	A	3/1999	Tang et al.	
6,313,158	B1 *	11/2001	Tang et al.	
6,395,734	B1 *	5/2002	Tang et al.	

FOREIGN PATENT DOCUMENTS

AU	286870	12/1964
CA	2012634	9/1991
DE	876539	6/1953
DE	2159360	6/1973
DE	2159361	6/1973
DE	2159362	6/1973
DE	2159363	6/1973
DE	2321656	11/1973
DE	3310891	9/1984
DE	3426419	1/1986
EP	0351213	1/1990
EP	0 252 713 B1	9/1990
EP	0566266	1/1993
EP	0525472	2/1993
EP	0580502	1/1994
EP	0632102	6/1994
EP	0626377	11/1994

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 09/762,198 filed Feb. 5, 2001, Tang et al.*
Desimoni et al., "Catalysis with Inorganic Cations. V.[1] Intramolecular Hetero Diels–Alder versus Ene Reactions: Effect of Magnesium Perchlorate on Chemoselectivity," *Tetrahedron*, 1996, pp. 12005–12018. vol. 52, No. 38. Elsevier Science Ltd.
Gibson et al., "Cleavage of Halogenobenzophenones by Potassamide in Ammonia; New Routes to Xanthem– and Thioxanthen–9–ones," *J.C.S. Perkin I*, 1975, pp. 155–160.
Kulka et al., "t–Butyl as a Blocking Group in the Synthesis of o Hydroxybenzophenones," Nov. 5, 1954, pp. 5469–5471.

(Continued)

Primary Examiner—Joseph K. McKane
Assistant Examiner—Kamal Saeed
(74) *Attorney, Agent, or Firm*—Beth A. Burrous; Foley & Lardner LLP

(57) **ABSTRACT**

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

2 Claims, 56 Drawing Sheets

US006906092B2

(12) **United States Patent**
O'Brien et al.

(10) **Patent No.: US 6,906,092 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **METHOD OF INHIBITING MATRIX METALLOPROTEINASES**

(75) Inventors: **Patrick Michael O'Brien**, Stockbridge, MI (US); **Joseph Armand Picard**, Canton, MI (US); **Drago Robert Sliskovic**, Saline, MI (US); **Andrew David White**, Pinckney, MI (US)

(73) Assignee: **Warner-Lambert Company**, Morris Plains, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 107 days.

(21) Appl. No.: **10/603,677**

(22) Filed: **Jun. 25, 2003**

(65) **Prior Publication Data**

US 2004/0029945 A1 Feb. 12, 2004

Related U.S. Application Data

(62) Division of application No. 10/162,518, filed on Jun. 4, 2002, now Pat. No. 6,620,835, which is a division of application No. 09/254,384, filed as application No. PCT/US97/14859 on Aug. 22, 1997, now Pat. No. 6,624,177

(60) Provisional application No. 60/025,062, filed on Sep. 4, 1996, and provisional application No. 60/055,713, filed on Aug. 7, 1997.

(51) **Int. Cl.**[7] **A61K 31/40**

(52) **U.S. Cl.** **514/411**; 514/443; 514/444; 514/468; 514/601; 514/602; 514/603; 514/604; 514/605

(58) **Field of Search** 514/411, 443, 514/444, 468, 601–605

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,845,097	A *	10/1974	Toyoshima et al.	560/28
3,850,968	A *	11/1974	Toyoshima et al.	549/494
3,919,291	A *	11/1975	Toyoshima et al.	560/159
4,066,773	A *	1/1978	Okamoto et al.	514/319
4,097,472	A *	6/1978	Okamoto et al.	514/20
5,627,206	A *	5/1997	Hupe et al.	514/468
5,663,704	A *	9/1997	Hupe et al.	514/468
5,948,780	A *	9/1999	Peterson et al.	514/255.01
6,207,698	B1 *	3/2001	Wantanabe et al.	514/414

FOREIGN PATENT DOCUMENTS

DE	20 65 966		7/1977
DE	2065966	*	7/1977
DE	20 65 966		11/1978
EP	183271	*	11/1985
EP	183271	*	6/1986
EP	0 183 271		5/1990
EP	0 606 046		7/1994
EP	606046	*	7/1994
EP	0 606 046		10/1997
JP	51105048	*	9/1976
JP	0 183 271	*	11/1985
WO	WO 96/38434 A1	*	12/1996
WO	96 38434		12/1996
WO	WO 96 38434		12/1996
WO	97 19068		5/1997
WO	WO 97 19068		5/1997
WO	WO 97/19068 A1	*	5/1997
WO	97 27174		7/1997
WO	WO 97/27174 A1	*	7/1997
WO	WO 97 27174		7/1997

OTHER PUBLICATIONS

Polman, C.H. et al, BMJ 2000, 321, 490–4.*

Cohen, J.A. et al, J. Neuroimmun , 1999. 98 29–36.*

Chemical Abstracts document No. 86:30073, 1976.*

Dubois B, D'Hooghe MB, De Lepeleire K, Ketelaer P, Opdebeeckx G, Carton H., Mult Scler Apr. 1998;4(2):74–8, cited in PMID: 9599337.*

"Cecil Textbook of Medicine, 20th Edition", Bennett, J.C. Editor, W.B. Saunders, Philadephia, 1996, pp. LVIII–LIX.*

"Merck Manual Diagnosis and Therapy, 16th Edition", Berkow, R. Editor–in–Chief, Merck Research Laboratories, Rahway, N.J., 1992, pp. 2792–2793.*

Skiles, J.W. et al, Annual Reports in Medical Chemistry, vol. 35, Academic Press, San Diego, 2000, pp. 167–176.*

Abdel–Ghaffer, et al. "Synthesis of Biologically Active Fluorene–2–sulphonylamino Acid and Dipeptide Derivatives", J. Serb. Chem. Soc., vol. 55, No. 6, 1990, pp 311–317.*

El–Naggar et al., "Synthesis and Biological Activity of Some New Dibenzofuran and 7–Nitrodibenzofuran–2–sulphonylamino Acid Derivatives", V–35, Acta Pharm. Jugosl., 1985, 15–22.*

Bennett, J.C. Editor, "Cecil Textbook of Medicine, 20th Edition", W.B. Saunders, Philadelphia, 1996, pp. LVII–LIX.*

(Continued)

Primary Examiner—Dwayne Jones
(74) *Attorney, Agent, or Firm*—Pfizer Inc.; Charles W. Ashbrook; Claude F. Purchase, Jr.

(57) **ABSTRACT**

The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I



More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

3 Claims, No Drawings

US006906091B2

(12) **United States Patent**
Camden

(10) **Patent No.: US 6,906,091 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **METHOD OF CANCER TREATMENT**

(75) Inventor: **James Berger Camden**, West Chester, OH (US)

(73) Assignee: **UAF Technologies and Research, LLC**, Tucson, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/198,334**

(22) Filed: **Jul. 18, 2002**

(65) **Prior Publication Data**

US 2003/0032664 A1 Feb. 13, 2003

Related U.S. Application Data

(63) Continuation of application No. 09/374,717, filed on Aug. 13, 1999, now Pat. No. 6,423,734.

(51) **Int. Cl.**[7] **A61K 31/415**
(52) **U.S. Cl.** **514/388**; 514/388
(58) **Field of Search** 514/388

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,933,502	A	4/1960	Klopping
3,010,968	A	11/1961	Loux
3,370,957	A	2/1968	Wagner et al.
3,399,212	A	8/1968	Hoover et al.
3,480,642	A	11/1969	Stedman et al.
3,499,761	A	3/1970	Dersch et al.
3,541,213	A	11/1970	Klopping
3,574,845	A	4/1971	Actor et al.
3,669,969	A	6/1972	Lunn
3,738,995	A	6/1973	Adams et al.
RE28,403	E	4/1975	Actor et al.
3,881,014	A	4/1975	Regel et al.
3,933,846	A	1/1976	Daum
3,956,262	A	5/1976	Heyes et al.
4,001,423	A	1/1977	Dodds
4,046,906	A	9/1977	Frensch et al.
4,053,598	A	10/1977	Daum et al.
4,086,235	A	4/1978	Beard
4,731,366	A	3/1988	Munro et al.
4,814,329	A	3/1989	Hansanyi et al.
5,098,923	A	3/1992	Karjalainen et al.
5,114,951	A	5/1992	King
5,149,527	A	9/1992	Weisenthal
5,284,662	A	2/1994	Koparkar et al.
5,290,801	A	3/1994	Higley et al.
5,310,748	A	5/1994	Wilde et al.
5,329,012	A	7/1994	Anderson
5,364,875	A	11/1994	Wilde
5,434,163	A	7/1995	Edlind et al.
5,441,742	A	8/1995	Autant et al.

(Continued)

FOREIGN PATENT DOCUMENTS

BE		667158	11/1965
DE		2144505 A1	3/1973
EP		0617968 A1	10/1994
FR		2046114	3/1971
FR		2135888	10/1973
GB		1123317	8/1968
GB		1296561	11/1972
GB		1397886	6/1975
IN		158878 A	2/1987
IN		159210 A	4/1987
JP		S42-23274 A	5/1963
JP		>1042565 A2	11/1975
JP		51034161 A2	3/1976
JP		H06-505733	6/1994
JP		07277956	10/1995
WO		WO 94/04541	3/1994
WO		WO 96/32103	10/1996
WO		WO 96/32104	10/1996
WO		WO 96/32107	10/1996
WO		WO 96/32115	10/1996

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 09/360,499, filed Jul. 26, 1999, Camden.
U.S. Appl. No. 09/371,457, filed Aug. 10, 1999, Camden.
U.S. Appl. No. 09/371,459, filed Aug. 10, 1999, Camden.
U.S. Appl. No. 09/312,948, filed May 17, 1999, Camden.
U.S. Appl. No. 09/394,383, filed Sep. 10, 1999, Camden.
U.S. Appl. No.08/857,811, filed May 16, 1997, CPA filed Jul. 28, 1999, Camden.
U.S. Appl. No. 09/462,243, filed Jan. 5, 2000, Camden.
U.S. Appl. No. 09/552,825, filed Apr. 20, 2000, Camden.
U.S. Appl. No. 09/552,820, filed Apr. 20, 2000, Camden.
U.S. Appl. No. 09/560,059, filed Apr. 27, 2000, Camden.

(Continued)

Primary Examiner—Rebecca Cook
(74) *Attorney, Agent, or Firm*—Haynes and Boone, LLP

(57) **ABSTRACT**

Methods of treating and inhibiting cancer in animals by administering a therapeutically effective amount of a pharmaceutical composition having benzimidazole of the general formula:



wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, oxychloro, nitro, methyl or ethyl; and R is hydrogen, or an alkyl group of from 1 to 8 carbon atoms and R_2 is NHCOOR, wherein R_1 is aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms and pharmaceutically acceptable derivatives alone, or in combination, or in conduction with other therapeutic agents such as other cancer inhibiting compounds, and operative combinations thereof.

10 Claims, No Drawings

(12) **United States Patent**
Janakiraman

(10) **Patent No.: US 6,906,090 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL DISEASES**

(75) Inventor: **Ramachandran Janakiraman**, Bangalore (IN)

(73) Assignee: **AstraZeneca AB**, Sodertalje (SE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/284,516**

(22) PCT Filed: **Mar. 4, 1999**

(86) PCT No.: **PCT/SE99/00319**

§ 371 (c)(1),
(2), (4) Date: **Apr. 14, 1999**

(87) PCT Pub. No.: **WO99/44608**

PCT Pub. Date: **Sep. 10, 1999**

(30) **Foreign Application Priority Data**

Mar. 6, 1998 (IN) 464/MAS/98
Apr. 20, 1998 (SE) 9801370

(51) **Int. Cl.**[7] **A61K 31/415**; A61K 31/40; A61K 31/445; A61K 31/55

(52) **U.S. Cl.** **514/387**; 514/418; 514/217.8; 514/217.9; 514/321; 514/322; 514/323; 540/575; 540/602; 540/603; 544/370; 544/373; 546/199; 546/201; 548/306.4; 548/486; 548/485

(58) **Field of Search** 514/387, 418, 514/217.8, 217.9, 321, 322, 323; 540/575, 602, 603; 544/370, 373; 546/199, 201; 548/306.4, 486, 485

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,382,934 A * 5/1983 Teraji et al. 514/254.09
5,585,378 A * 12/1996 Boar et al. 514/254.09

FOREIGN PATENT DOCUMENTS

EP	0432648	6/1991
EP	0503349	9/1992
WO	9312085	6/1993
WO	WO 93/12085 *	6/1993
WO	9429272	12/1994
WO	WO 94/29272 *	12/1994

OTHER PUBLICATIONS

Piscopo et al., Boll. Soc. It. Biol. Sper. 52:1449–1455 (1986).
Verma et al., Indian J. Chem. 21B: 775–777 (1982).
Movrin et al., Pharmazie 34: 231–232 (1979).

* cited by examiner

Primary Examiner—D. Margaret Seaman
(74) *Attorney, Agent, or Firm*—White & Case LLP

(57) **ABSTRACT**

The invention provides the use of certain isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease.

7 Claims, No Drawings

US006906089B2

(12) **United States Patent**
Gaster et al.

(10) **Patent No.: US 6,906,089 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS**

(75) Inventors: **Laramie Mary Gaster**, Harlow (GB); **John David Harling**, Harlow (GB)

(73) Assignee: **SmithKline Beecham Corporation**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl No.: **10/239,815**

(22) PCT Filed: **Mar. 26, 2001**

(86) PCT No.: **PCT/GB01/01314**

§ 371 (c)(1),
(2), (4) Date: **Jan. 21, 2003**

(87) PCT Pub. No.: **WO01/72737**

PCT Pub. Date: **Oct. 4, 2001**

(65) **Prior Publication Data**

US 2003/0149277 A1 Aug. 7, 2003

(30) **Foreign Application Priority Data**

Mar. 27, 2000 (GB) 0007405

(51) **Int. Cl.**[7] **A61K 31/443**; A61K 31/4436; A61K 31/4439; C07D 401/04; C07D 405/04

(52) **U.S. Cl.** **514/341**; 514/341; 514/342; 514/343; 546/268.7; 546/269.4; 546/272.7; 546/280.4; 546/283.4

(58) **Field of Search** 546/268.7, 269.4, 546/276.4, 272.7, 280.4, 283.4, 274.1; 514/341, 342, 343

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,955,480 A 9/1999 Chang 514/341

FOREIGN PATENT DOCUMENTS

GB	1 381 031	1/1975
JP	A11 180 958	7/1999
WO	WO9314081	7/1993
WO	WO9821957	5/1998
WO	WO0061576	10/1999

OTHER PUBLICATIONS

Inman, Gareth J. et al, "SB-431542 is a Potent and Specific Inhibitor of TGF-b Superfamily Type I ALK Receptors ALK4, ALK5, & ALK7," Molecular Pharmacology (2002), vol. 62 (1), pp. 65-74.*

* cited by examiner

Primary Examiner—Cecilia Chang
Assistant Examiner—Janet L. Coppins
(74) *Attorney, Agent, or Firm*—Nora Steiu-Fernandez; Theodore R. Furman

(57) **ABSTRACT**

Compounds of formula (I) or a pharmaceutically acceptable salt thereof:

(I)



wherein R_1, R_2 and R_3 are various substituent groups; and one of X_1 and X_2 is N or CR", and the other is NR" or CHR" wherein R" is hydrogen, OH, C_{1-6}alkyl, or C_{3-7}cycloalkyl; or when one of X_1 and X_2 is N or CR" then the other may be S or O;

and their use as pharmaceuticals.

9 Claims, No Drawings

(12) **United States Patent**
Holton et al.

(10) **Patent No.: US 6,906,088 B2**
(45) **Date of Patent: *Jun. 14, 2005**

(54) **TAXANES HAVING A C10 CARBAMOYLOXY SUBSTITUENT**

(75) Inventors: **Robert A. Holton**, Tallahassee, FL (US); Weishuu Faug, Bejiang (CN)

(73) Assignee: **FSU Research Foundation, Inc.**, Tallahassee, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 19 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/618,063**

(22) Filed: **Jul. 11, 2003**

(65) **Prior Publication Data**

US 2004/0034230 A1 Feb. 19, 2004

Related U.S. Application Data

(63) Continuation of application No. 09/775,852, filed on Feb. 2, 2001, now Pat. No. 6,596,737.
(60) Provisional application No. 60/179,793, filed on Feb. 2, 2000.

(51) **Int. Cl.**[7] **A61K 31/4427**; A61K 31/381; A61K 31/341; A61K 31/337; C07D 305/14

(52) **U.S. Cl.** **514/337**; 514/444; 514/471; 514/473; 514/449, 546/281.7; 549/60; 549/471; 549/510; 549/511

(58) **Field of Search** 414/337; 514/444, 514/471, 473, 449; 546/281.7; 549/60, 471, 510, 511

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,175,315	A	12/1992	Holton
5,227,400	A	7/1993	Holton et al.
5,243,045	A	9/1993	Holton et al.
5,283,253	A	2/1994	Holton et al.
5,350,866	A	9/1994	Holton et al.
5,430,160	A	7/1995	Holton
5,556,878	A	9/1996	Kelley et al.
5,567,614	A	10/1996	Patel et al.
5,714,513	A	2/1998	Holton et al.
5,721,268	A	2/1998	Holton et al.
5,780,653	A	7/1998	Tao et al.
5,811,452	A	9/1998	Ojima et al.
5,879,929	A	3/1999	Patel
5,906,990	A	5/1999	Bouchard et al.
5,912,264	A	6/1999	Wittman et al.
5,959,125	A	9/1999	Bouchard et al.
6,100,411	A	8/2000	Ojima

FOREIGN PATENT DOCUMENTS

EP	0 524 093	A1	1/1993
EP	0 558 959	A1	9/1993
EP	0 600 517	B1	6/1994
EP	0 629 701	B1	12/1994
WO	WO 93/02065	A1	2/1993
WO	WO 93/23389	A1	11/1993
WO	WO 96/13495	A1	5/1996
WO	WO 97/09979	A1	3/1997
WO	WO 97/32578	A1	9/1997
WO	WO 97/42181	A1	11/1997
WO	WO 98/02426	A1	1/1998
WO	WO 99/09021	A1	2/1999
WO	WO 99/14209	A1	3/1999
WO	WO 99/32473	A1	7/1999
WO	WO 00/53592	A1	9/2000
WO	WO 01/57013	A1	8/2001

OTHER PUBLICATIONS

Dubois, J. et al., "Fluorescent and Biotinylated Analogues of Docetaxel: Synthesis and Biological Evaluation", Bioorganic & Medicinal Chemistry, (1995), pp. 1357–1368, vol. 3:10.
Gueritte–Voegelein et al. "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity" Journal of Medicinal Chemistry, vol. 34, No. 3 (1991) pp. 992–998.
Kant et al. "A Chemoselective Approach to Functionalize the C–10 Position of 10–Deacetylbaccatin III. Synthesis and Biological Properties of Novel C–10 Taxol Analogues" Tetrahedron Letters, vol. 35, No. 30 (1994) pp. 5543–5546.
Kirikae et al. "Structural Significance of the Acyl Group at the C–10 Position and the A Ring of the Taxane Core of Paclitaxel for Inducing Nitric Oxide and Tumor Necrosis Factor Production by Murine Macrophages" FEBS Letters, vol. 478 (2000) pp. 221–226.
Ojima et al. "Synthesis and Biological Activity of Novel 3'–trifluoromethyl Taxoids" Bioorganic and Medicinal Chemistry Letters, vol. 7, No. 2 (1997) pp. 133–138.
Ojima et al. "Enantiopure Fluorine–containing Taxoids: Potent Anticancer Agents and Versatile Probes for Biomedical Problems" Journal of Fluorine Chemistry, vol. 97 (1999) pp. 3–10.
Ojima et al. "Synthesis and Structure–Activity Relationships of the Second–Generation Antitumor Taxoids: Exceptional Activity Against Drug–Resistant Cancer Cells" Journal of Medicinal Chemistry, vol. 39, No. 20 (1996) pp. 3889–3896.
Ojima et al. "Syntheses and Biological Activity of C–3'–Difluoromethyl–Taxoids" Bioorganic & Medicinal Chemistry, vol. 8 (2000) pp. 1619–1628.
Ojima et al. "Synthesis of Novel 3'–Trifluoromethyl Taxoids Through Effective Kinetic Resolution of Racemic 4–CF_3–β–Lactams With Baccatins" Chirality, vol. 9 (1997) pp. 487–494.
Straubinger et al. "Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations" Chapter 8, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 111–123.
International Search Report from PCT/US01/03633 dated Jun. 11, 2001.

Primary Examiner—Ba K. Trinh
(74) *Attorney, Agent, or Firm*—Senniger Powers

(57) **ABSTRACT**

Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.

32 Claims, No Drawings

(12) **United States Patent**
Van Der Schaaf et al.

(10) **Patent No.: US 6,906,087 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **CRYSTALLINE FORMS OF VENLAFAXINE HYDROCHLORIDE**

(75) Inventors: **Paul Adriaan Van Der Schaaf**, Allschwil (CH); **Claudia Marcolli**, Zürich (CH); **Martin Szelagiewicz**, Münchenstein (CH); **Beat Freiermuth**, Buschwiller (FR)

(73) Assignee: **Ciba Specialty Chemicals Corpation**, Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/130,042**

(22) PCT Filed: **Oct. 23, 2001**

(86) PCT No.: **PCT/EP01/12240**

§ 371 (c)(1),
(2), (4) Date: **Oct. 1, 2002**

(87) PCT Pub. No.: **WO02/36542**

PCT Pub. Date: **May 10, 2002**

(65) **Prior Publication Data**

US 2003/0105359 A1 Jun. 5, 2003

(30) **Foreign Application Priority Data**

Oct. 31, 2000 (EP) 00811014

(51) **Int. Cl.**[7] **A61K 31/135**

(52) **U.S. Cl.** **514/336**; 564/336; 564/355; 564/424; 564/425; 564/360

(58) **Field of Search** 514/646, 649; 564/336, 355, 424, 425, 360

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,043,466	A	8/1991	Shepard	558/371
2002/0143211	A1 *	10/2002	Dolitzky et al.	564/316
2002/0183553	A1 *	12/2002	Dolitzky et al.	564/316
2003/0105359	A1 *	6/2003	Van Der Schaaf et al.	564/339
2003/0109585	A1 *	6/2003	Ali et al.	514/649

FOREIGN PATENT DOCUMENTS

EP	0112660	7/1984
EP	0444855	9/1991
WO	02/45658	6/2002
WO	02/46140	6/2002

OTHER PUBLICATIONS

J. Yardley et al., J. Med. Chem. (1990), vol. 33, pp. 2899–2905.

* cited by examiner

Primary Examiner—Samuel Barts
(74) *Attorney, Agent, or Firm*—Kevin T. Mansfield

(57) **ABSTRACT**

Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

4 Claims, 6 Drawing Sheets

US006906085B2

(12) **United States Patent**
Castro Pineiro et al.

(10) **Patent No.: US 6,906,085 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **TETRAHYDROPYRAN DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS**

(75) Inventors: **Jose Luis Castro Pineiro**, Bishops Stortford (GB); **Piotr Antoni Raubo**, Bishops Stortford (GB); **Christopher John Swain**, Duxford (GB)

(73) Assignee: **Merck Sharp & Dohme Ltd.**, Hoddesdon

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/466,700**

(22) PCT Filed: **Jan. 16, 2002**

(86) PCT No.: **PCT/GB02/00179**

§ 371 (c)(1),
(2), (4) Date: **Jul. 15, 2003**

(87) PCT Pub. No.: **WO02/057250**

PCT Pub. Date: **Jul. 25, 2002**

(65) **Prior Publication Data**

US 2004/0063974 A1 Apr. 1, 2004

(30) **Foreign Application Priority Data**

Jan. 17, 2001 (GB) 0101246
Sep. 10, 2001 (GB) 0121876

(51) **Int. Cl.**[7] **A61K 31/35**; A61K 31/445; C07D 309/10; C07D 401/04; C07D 401/06

(52) **U.S. Cl.** **514/326**; 514/382; 514/383; 514/384; 514/459; 514/460; 546/207; 549/416; 549/419; 548/252; 548/263.2; 548/268.8

(58) **Field of Search** 546/207; 548/252, 548/263.2, 268.8; 514/382, 383, 384, 460, 459; 549/416, 419, 423

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 0056727 A 9/2000

OTHER PUBLICATIONS

Chemical Abstracts Service, vol. 70, No. 25, Jun. 23, 1969, Y. Kai, M. Shimizu: "Phenolic constituents from *Cryptomeria joaponica* wood, V. Structure of hydroxysugiresinol" vol. 14, No. 8, 1986, pp. 430–433.

Primary Examiner—Bernard Dentz
(74) *Attorney, Agent, or Firm*—J. Eric Thies; Melvin Winokur

(57) **ABSTRACT**

The present invention relates compounds of the formula (I):

(I)



wherein R^1, R^2, R^3, R^4, R^5, R^6, R^7 and R^8 represent a variety of substituents; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

14 Claims, No Drawings

US006906083B2

(12) **United States Patent**
Iimura et al.

(10) **Patent No.: US 6,906,083 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **4-SUBSTITUTED PIPERIDINE COMPOUND**

(75) Inventors: **Yoichi Iimura**, Ibaraki (JP); **Takashi Kosasa**, Ibaraki (JP)

(73) Assignee: **Eisai Co., Ltd.**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/296,379**

(22) PCT Filed: **Jun. 21, 2001**

(86) PCT No.: **PCT/JP01/05320**

§ 371 (c)(1),
(2), (4) Date: **Nov. 25, 2002**

(87) PCT Pub. No.: **WO01/98271**

PCT Pub. Date: **Dec. 27, 2001**

(65) **Prior Publication Data**

US 2003/0166925 A1 Sep. 4, 2003

(30) **Foreign Application Priority Data**

Jun. 21, 2000 (JP) 2000-186085

(51) **Int. Cl.**[7] **A61K 31/445**; C07D 211/06; C07D 211/32

(52) **U.S. Cl.** **514/319**; 546/205; 546/206

(58) **Field of Search** 514/319; 546/205, 546/206

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,100,901	A	3/1992	Sugimoto et al.	514/319
6,277,866	B1	8/2001	Takeuchi et al.	514/319
6,677,330	B1 *	1/2004	Iimura et al.	514/183
2002/0177593	A1	11/2002	Ishihara et al.	514/227.5
2004/0048893	A1	3/2004	Lerman et al.	514/319

FOREIGN PATENT DOCUMENTS

EP	0 602 424	A1	6/1994
JP	9-268176	A	10/1997
JP	2000-319257	A	11/2000
WO	92/17475	A1	10/1992
WO	WO 00/18391	A1	4/2000
WO	WO 00/51985	A1	9/2000
WO	WO 00/57880	A1	10/2000
WO	WO 02/02526	A1	1/2002

OTHER PUBLICATIONS

Wilbraham et al. "Introduction to organic and biological chemistry" S. III. Univ. press p. 268–269 (1984).

* cited by examiner

Primary Examiner—Celia Chang
(74) *Attorney, Agent, or Firm*—Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The present invention provides a novel compound having a superior acetylcholinesterase inhibitory action. It provides a compound represented by the formula:

(I)



(In the formula, R^1 represents a group represented by the formula:



(wherein, R^3, R^4, R^5 and R^6 are the same as or different from each other and each represents a hydrogen atom, an optionally substituted C_{1-6} alkoxy group and the like; and m represents an integer from 0 to 6) and the like; and R^2 represents a hydrogen atom, an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{2-6} alkenyl group or an optionally substituted C_{2-6} alkynyl group), a salt thereof or a hydrate of them.

19 Claims, No Drawings

(12) **United States Patent**
DeNinno et al.

(10) **Patent No.: US 6,906,082 B2**
(45) **Date of Patent: *Jun. 14, 2005**

(54) **4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES**

(75) Inventors: **Michael P. DeNinno**, Gales Ferry, CT (US); **George T. Magnus-Aryitey**, Ledyard, CT (US); **Roger B. Ruggeri**, Waterford, CT (US); **Ronald T. Wester**, Ledyard, CT (US)

(73) Assignee: **Pfizer Inc.**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/607,640**

(22) Filed: **Jun. 27, 2003**

(65) **Prior Publication Data**

US 2004/0092550 A1 May 13, 2004

Related U.S. Application Data

(62) Division of application No. 09/685,380, filed on Oct. 10, 2000, now Pat. No. 6,586,448, which is a division of application No. 09/391,152, filed on Sep. 7, 1999, now Pat. No. 6,197,786.

(60) Provisional application No. 60/100,860, filed on Sep. 17, 1998.

(51) **Int. Cl.**[7] **A61K 31/47**; C07D 215/38

(52) **U.S. Cl.** **514/313**; 546/159

(58) **Field of Search** 514/313; 546/159

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,231,101	A	7/1993	Honda et al.	514/290
5,231,102	A	7/1993	Baker et al.	514/312
5,276,168	A	1/1994	Atwal	549/404
5,288,725	A	2/1994	Witherup et al.	514/292
5,401,848	A	3/1995	Atwal	546/153
5,932,587	A	8/1999	Schmeck et al.	514/278
6,140,342	A	10/2000	Goldstein et al.	514/313
6,140,343	A	10/2000	DeNinno et al.	514/313
6,147,089	A	11/2000	DeNinno et al.	514/313
6,147,090	A	11/2000	DeNinno et al.	514/313
6,197,786	B1 *	3/2001	DeNinno et al.	514/313
6,310,075	B1	10/2001	DeNinno et al.	514/313
6,362,198	B1	3/2002	Goldstein et al.	514/313
6,395,751	B1	5/2002	DeNinno et al.	514/313
6,489,478	B1	12/2002	DeNinno et al.	546/159
6,586,448	B1 *	7/2003	DeNinno et al.	514/313

FOREIGN PATENT DOCUMENTS

EP	0818448	11/2003	C07D/215/20
EP	0818197	12/2003	A61K/31/435
WO	WO 0038722	7/2000	A61K/45/06

OTHER PUBLICATIONS

Gordon, D.J., et al., "High Density lipoprotein cholesterol and cardiovascular disease. Four prospective American Studies.", *Circulation*, vol. 79, No. 1, pp. 8–15 (1989).
Chem. Abstract, vol. 116, 1992, 116:151569g.
Chem. Abstracts vol. 123, 1995, 123:55716b.

* cited by examiner

Primary Examiner—D. Margaret Seaman
(74) *Attorney, Agent, or Firm*—Gregg C. Benson; Peter C. Richardson; A. Dean Olson

(57) **ABSTRACT**

Cholesteryl ster transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

15 Claims, No Drawings

US006906080B1

(12) **United States Patent**
Barth et al.

(10) **Patent No.: US 6,906,080 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME**

(75) Inventors: **Francis Barth**, Saint-Georges-D'Orques (FR); **Christian Congy**, Saint-Gely-du-Fesc (FR); **Serge Martinez**, Montpellier (FR); **Murielle Rinaldi**, Saint-Georges-D'Orques (FR)

(73) Assignee: **Sanofi-Aventis**, Paris (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/111,765**

(22) PCT Filed: **Nov. 2, 2000**

(86) PCT No.: **PCT/FR00/03049**

§ 371 (c)(1),
(2), (4) Date: **Jul. 30, 2002**

(87) PCT Pub. No.: **WO01/32663**

PCT Pub. Date: **May 10, 2001**

(30) **Foreign Application Priority Data**

Nov. 3, 1999 (FR) 99 13846

(51) **Int. Cl.**[7] **C07D 495/04**; A61K 31/4162; A61K 31/4439; A61K 31/438

(52) **U.S. Cl.** **514/278**; 514/322; 514/406; 546/16; 546/199; 548/359.5

(58) **Field of Search** 548/359.5; 514/406, 514/322, 278; 546/199, 16

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,940,418	A	2/1976	Hamilton
5,420,141	A	5/1995	Boigegrain et al.
5,462,960	A	10/1995	Barth et al.
5,624,941	A	4/1997	Barth et al.
6,028,084	A	2/2000	Barth et al.

FOREIGN PATENT DOCUMENTS

EP	0477049	3/1992
EP	0568546	11/1993
EP	576357	12/1993
EP	0658546	12/1994
WO	WO 96/09304	3/1996
WO	WO 97/19063	5/1997

OTHER PUBLICATIONS

Hamilton, R.W., Journal of Heterocyclic Chemistry, vol. 13, No. 3, pp. 545–553 (1976).
Fravolini, A. et al., Farmaco, Ed. Sci., vol. 33, No. 11, pp. 855–860 (1978).

Primary Examiner—Joseph K. McKane
Assistant Examiner—Rebecca Anderson
(74) *Attorney, Agent, or Firm*—Kelly Bender

(57) **ABSTRACT**

The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula:

(I)



in which R_1 represents a C_3–C_{15} carboxyl radical or an NR_2R_3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB_1 receptors.

11 Claims, No Drawings

US006906079B2

(12) **United States Patent**
Gutman et al.

(10) **Patent No.: US 6,906,079 B2**
(45) **Date of Patent: *Jun. 14, 2005**

(54) **METHOD AND REAGENTS FOR N-ALKYLATING UREIDES**

(75) Inventors: **Daniela Gutman**, Rishon Lezion (IL); **Hershel Herzog**, Tarrytown, NY (US)

(73) Assignee: **Taro Pharmaceutical Industries Limited**, Haifa Bay (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/687,712**

(22) Filed: **Oct. 17, 2003**

(65) **Prior Publication Data**

US 2004/0167358 A1 Aug. 26, 2004

Related U.S. Application Data

(63) Continuation of application No. 10/073,051, filed on Feb. 12, 2002, now Pat. No. 6,664,262, which is a continuation of application No. 09/609,902, filed on Jun. 30, 2000, now abandoned, which is a continuation of application No. 08/942,636, filed on Oct. 2, 1997, now Pat. No. 6,093,820.

(51) **Int. Cl.**[7] **A61P 25/00; A61K 31/515**

(52) **U.S. Cl.** **514/270**

(58) **Field of Search** 514/270

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,673,205	A	3/1954	Hoffman et al.
4,628,056	A	12/1986	Levitt et al.
6,093,820	A	7/2000	Gutman et al.
6,184,238	B1	2/2001	Takano et al.
6,372,757	B1	4/2002	Johns et al.
6,664,262	B2	12/2003	Gutman et al.

FOREIGN PATENT DOCUMENTS

DE	1939787	2/1970
DE	2622981	12/1977
DE	4028040	3/1992
EP	726252	1/1996
EP	1 083 172 A1	3/2001
WO	WO-01/79185 A1	10/2001
WO	W.O-02/07729	1/2002

OTHER PUBLICATIONS

Masuda et al.: "Relationships Between Plasma Concentrations of Diphenylhydantoin, Phenobarbital, Carbamazepine, and 3-Sulfamoylmethyl-1,2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals"; Epilepsia, vol. 20, Dec. 1979, pp. 623–633.

Bhardwaj et al.: "Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum"; Journal of Neural Transmission [GenSect] (1990) 82; pp. 111–117.

Samour et al.: "Anticonvulsants. 1. Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin"; Journal of Medicinal Chemistry, 1971, vol. 14, No. 3 pp. 187–189.

Casara et al.: "Synthesis of Acid Stable Fluorinated Acyclonucleosides as Potential Antiviral Agents"; Tetrahedron Letters, vol. 32, No. 31, pp. 3823–3826, 1991.

Sircar: "CLXXIII.–The Influence of Groups and Associated Rings on the Stability of Certain Heterocyclic Systems. Part II. The Substituted Succinimides"; Journal of the Chemical Society, May 1927, pp. 1252–1258.

The Merck Index; An Encyclopedia of Chemicals, Drugs and Biologicals; Tenth Edition, Published by Merck & Co., Inc., Rahway, NJ, USA, 1983, p. 544, (entry 3697).

Salmon–Legagneur et al.: "Recherches dans la serie des diacides αα–disubstitutes et de leurs derives. III. – Les acides a–phenyl a–alcoyl (ou phenoalcoyl) glutariques et leurs principaux derives"; Bull. Soc. Chim. France (1953) p. 70–75.

Salmon–Legagneur et al: "Sur les acides a–phenyl a–alcoyl (ou phenoalcoyl) glutariques"; Comptes Rendus de l'Academie des Sciences, (Mar. 3, 1952) p. 1060–1062.

Tagmann et al: Helv. Chim. Acta 35, 1541–1549 (1952).

McElvain: "5,5–Diphenylbarbituric Acid"; vol. 57, pp. 1303–1304, (1935).

(Continued)

Primary Examiner—Bruck Kifle

(57) **ABSTRACT**

A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I:

I



with an alkylating agent of structure III:

III



in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N'-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.

7 Claims, No Drawings

(12) **United States Patent**
Pang

(10) **Patent No.: US 6,906,077 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF OPHTHALMIC NEURODEGENERATIVE DISEASES**

(75) Inventor: **Iok-hou Pang**, Grand Prairie, TX (US)

(73) Assignee: **Alcon Manufacturing, Ltd.**, Fort Worth, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/856,987**

(22) PCT Filed: **Dec. 1, 1999**

(86) PCT No.: **PCT/US99/28385**

§ 371 (c)(1),
(2), (4) Date: **May 25, 2001**

(87) PCT Pub. No.: **WO00/32197**

PCT Pub. Date: **Jun. 8, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/110,983, filed on Dec. 3, 1998.

(51) **Int. Cl.**[7] **A61K 31/52**

(52) **U.S. Cl.** **514/261**; 514/912

(58) **Field of Search** 514/261, 912

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,550,022 A		10/1985	Garabedian et al.	424/127
5,641,749 A	*	6/1997	Yan et al.	514/12
5,641,750 A		6/1997	Louis	514/12

FOREIGN PATENT DOCUMENTS

WO	98/10758	10/1998

OTHER PUBLICATIONS

Van Buskirk, et al., "Predicted outcome from hypotensive therapy for glaucomatous optic neuropathy," *Am. J. Ophthalmol.*, vol. 116(5):636 640, (1993).

Schumer, et al., "The nerve of glaucoma!," *Arch. Ophthalmol.*, vol. 112:37–44, (1994).

Raff, et al., "Programmed cell death and the control of cell survival: lessons from the nervous systems," *Science*, vol. 262:695–700, (1993).

Anderson, et al., "Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve," *Invest. Ophthalmol.*, vol. 13(10):771–783, (1974).

Quigley, et al., "The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve," *Invest. Ophthalmol.*, vol. 15(8):606–616, (1976).

Mansour-Robaey, et al., "Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion . . . ," *Proc. Natl. Acad. Sci. USA*, vol. 91:1632–1636, (1994).

Meyer-Franke, et al., "Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture," *Neuron*, vol. 15:805–819, (1995).

Cui, et al., "NT-4/5 reduces naturally occurring retinal ganglion cell death in neonatal rats," *Neuroreport*, vol. 5(15):1882–1884, (1994).

Lewin, et al., "Physiology of the neurotrophins," *Ann. Rev. Neurosci.*, vol. 19:289–317, (1996).

Segal, et al., "Intracellular signaling pathways activated by neurotrophic factors," *Ann. Rev Neurosci.*, vol. 19:463–489, (1996).

Ebadi, et al., "Neurotrophins and their receptors in nerve injury and repair," *Neurochem Int.*, vol. 30(4/5):347–374, (1997).

Kaplan, et al., "Signal transduction by the neurotrophin receptors," *Curr. Opin. Cell Biol.*, vol. 9:213 221, (1997).

Jelsma, et al., "Different forms of the neurotrophin receptor trkB mRNA predominate in rat retina and optic nerve," *J. Neurobiol.*, vol. 24(9):1207–1214, (1993).

Rickman, et al., "Expression of the protooncogene, *trk*, receptors in the developing rat retina," *Vis. Neurosci.*, vol. 12:215–222, (1995).

Ugolini, et al., "TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina," *Brain Res*, vol. 704:121–124, (1995).

Cellerino, et al., "Brain-derived neurotrophic factor/neurotrophin-4 receptor TrkB is localized on ganglion cells and Dopaminergics amacrine cells in the vertebrate retina," *J. Comp. Neurol.*, vol. 386:149–160, (1997).

Gao, et al., "Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after Optic nerve injury," *Invest. Ophthalmol. Vis. Sci.*, vol. 38(9):1840–1847, (1997).

Lindholm, et al., "Brain derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity," *Eur. J. Neurosci.*, vol. 5:1455–1464, (1993).

Unoki, et al., "Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary Neurotrophic factor, and basic fibroblast growth factor," *Invest. Ophthalmol. Vis. Sci.*, vol. 35(3):907–915, (1994).

Beck, et al., "Brain-derived neurotrophic factor protects against ischemic cell damage in the rat hippocampus," *J. Cereb. Blood. Flow Metab.*, vol. 14:689–692, (1994).

Kirsch, et al., "Evidence for multiple, local functions of ciliary neurotrophic factor (CNTF) in retinal development: expression of CNTF and its receptors and in vitro . . . ," *J. Neurochem.*, vol. 68(3):979–990, (1997).

(Continued)

Primary Examiner—Zohreh Fay
(74) *Attorney, Agent, or Firm*—Teresa J. Schultz

(57) **ABSTRACT**

Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.

9 Claims, No Drawings

(12) **Unitcd States Patent**
DeSimone et al.

(10) **Patent No.: US 6,906,075 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES**

(75) Inventors: **Robert W. DeSimone**, Durham, CT (US); **Cheryl Steenstra**, Meriden, CT (US); **Linda Gustavson**, Guilford, CT (US); **Rajagopal Bakthavatchalam**, Madison, CT (US); **Alan Hutchison**, Madison, CT (US)

(73) Assignee: **Neurogen Corp.**, Branford, CT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 58 days.

(21) Appl. No.: **10/339,111**

(22) Filed: **Jan. 9, 2003**

(65) **Prior Publication Data**

US 2003/0216390 A1 Nov. 20, 2003

Related U.S. Application Data

(60) Provisional application No. 60/347,279, filed on Jan. 10, 2002.

(51) **Int. Cl.**[7] **C07D 401/10**; A61K 31/445; A61K 31/495

(52) **U.S. Cl.** **514/254.01**; 514/323; 514/399; 544/370; 546/201; 548/306.1

(58) **Field of Search** 548/306.1; 514/399, 514/254.01, 323; 546/201; 544/370

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,271,241 B1	8/2001	DeSimone et al.
6,358,949 B1	3/2002	DeSimone et al.
6,380,210 B1	4/2002	DeSimone et al.

FOREIGN PATENT DOCUMENTS

EP	1254668	11/2002
GB	1115390	5/1968
JP	09-124609	5/1997
JP	2001-226269	8/2001
WO	WO 00/59886	10/2000
WO	WO 00/59887	10/2000
WO	WO 00/59905	10/2000
WO	WO 01/00611	1/2001
WO	WO 01/21169	3/2001
WO	WO 01/21577	3/2001
WO	WO 01/82925	11/2001
WO	WO 01/87834	11/2001
WO	WO 02/02744	1/2002
WO	WO 02/04433	1/2002
WO	WO 02/06245	1/2002
WO	WO 02/28839	4/2002
WO	WO 02/50062	6/2002
WO	WO 02/051809	7/2002
WO	WO 02/057233	7/2002
WO	WO 02/076929	10/2002
WO	WO 02/076947	10/2002
WO	WO 02/083134	10/2002
WO	WO 02/089729	11/2002
WO	WO 02/092575	11/2002
WO	WO 03/004027	1/2003

Primary Examiner—Joseph K. McKane
Assistant Examiner—Golam M M Shameem
(74) *Attorney, Agent, or Firm*—Ann T. Kadlecek; Seth A. Fidel

(57) **ABSTRACT**

Melanin concentrating hormone receptor ligands (especially substituted benzoimidazole analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

16 Claims, No Drawings

US006906074B2

(12) **United States Patent**
Ogino et al.

(10) **Patent No.: US 6,906,074 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **2-PHENYLPIPERAZINE DERIVATIVES**

(75) Inventors: **Takashi Ogino**, Osaka (JP); **Yukari Konishi**, Hyogo (JP); **Kunihiko Higashimura**, Hyogo (JP); **Kazuhito Furukawa**, Hyogo (JP)

(73) Assignee: **Nippon Zoki Pharmaceutical Co., Ltd.**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 131 days.

(21) Appl. No.: **10/370,918**

(22) Filed: **Feb. 20, 2003**

(65) **Prior Publication Data**

US 2003/0166616 A1 Sep. 4, 2003

(30) **Foreign Application Priority Data**

Feb. 22, 2002 (JP) 2002-045562

(51) **Int. Cl.**[7] **C07D 241/08**; C07D 403/06; A61K 31/50; A61K 31/501

(52) **U.S. Cl.** **514/253.01**; 514/254.01; 514/254.05; 514/225.05; 514/255.03; 544/337; 544/360; 544/366; 544/372; 544/384; 544/389; 544/390; 544/391, 544/403

(58) **Field of Search** 514/253.01, 254.01, 514/254.05, 255.02, 255.03; 544/337, 360, 366, 372, 384, 389, 390, 391, 403

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,472,978	A	12/1995	Baker et al.	514/443
5,610,183	A	3/1997	Owens et al.	514/539
5,629,347	A	5/1997	Swain et al.	514/620
5,719,156	A	2/1998	Shue et al.	514/252.13
5,795,894	A	8/1998	Shue et al.	514/254.04
5,798,359	A	8/1998	Shue et al.	517/252.12
5,892,039	A	4/1999	Shue et al.	544/360
5,981,520	A	11/1999	Shue et al.	514/217.05

FOREIGN PATENT DOCUMENTS

GB	2271774	A	4/1994
JP	6509332	T	1/1993
JP	6509087	T	12/1995
JP	6509090	T	3/1997
WO	WO 01/70708	A1	9/2001

OTHER PUBLICATIONS

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ., Cancer. May 1, 2003;97(9):2290–300.*

Ranga K, Krishnan R, J Clin Psychiatry. 2002; 63 Suppl 11:25–9, Medline abstract PMID: 12562140.*

West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.*

Williams et al., *Acyclic NK–1 Antagonists: 2–Benzhydryl–2–Aminoethyl Ethers*, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 16, pp. 1903–1908, 1994.

Stevenson et al., *4,4–Disubstituted Piperidine High–affinity NK_1 Antagonists: Structure Activity Relationships and in Vivo Activity*, J. Med. Chem., 41, pp. 4623–4635, 1998.

Vedani et al., *Multiple–Conformation and Protonation–State Representation in 4D–QSAR: The Neurokinin–1 Receptor System*, J. Med. Chem., 43, pp. 4416–4427, 2000.

* cited by examiner

Primary Examiner—Thomas C. McKenzie
(74) *Attorney, Agent, or Firm*—Hollander Law Firm, P.L.C.

(57) **ABSTRACT**

A 2-phenylpiperazine derivative represented by the formula (I) or a pharmaceutically acceptable salt, hydrate, or complex thereof:

(I)



wherein each of X_1 and X_3 is oxygen or two hydrogen atoms, X_2 O, NH, NCH_3, or CH_2, n is an integer of 0 or 1, R_1 is hydrogen or lower alkyl and R_2 is hydrogen, cyano, tetrazolyl, aminotriazolyl , mesyl, t-butoxycarbonyl, or a lower alkyl which may be optionally substituted, R_3 is hydrogen, halogen, lower alkyl or lower alkoxy, each of R_4 and R_5 is hydrogen, lower alkoxy or trifluoromethyl, and a broken line indicates a single or double bond. The derivative may be used as a tachykinin antagonist in the treatment of diseases of the digestive system, nervous system and respiratory system, inflammation, allergy, carcinoid syndrome, chronic pain, headache, Crohn disease, depression and vomiting.

18 Claims, No Drawings

US006906073B2

(12) **United States Patent**
Du Bois et al.

(10) **Patent No.: US 6,906,073 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **PIPERAZINE CCR-3 RECEPTOR ANTAGONISTS**

(75) Inventors: **Daisy Joe Du Bois**, Palo Alto, CA (US); **Denis John Kertesz**, Mountain View, CA (US); **Eric Brian Sjogren**, Mountain View, CA (US); **David Bernard Smith**, San Mateo, CA (US); **Belhan Wang**, Santa Clara, CA (US)

(73) Assignee: **Roche Palo Alto LLC**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 49 days.

(21) Appl. No.: **10/307,159**

(22) Filed: **Nov. 29, 2002**

(65) **Prior Publication Data**

US 2003/0176441 A1 Sep. 18, 2003

Related U.S. Application Data

(60) Provisional application No. 60/334,655, filed on Nov. 30, 2001.

(51) Int. Cl.[7] A61K 31/495; C07D 241/04

(52) U.S. Cl. 514/252.13; 514/254.01; 514/254.1; 514/255.03; 544/372; 544/374; 544/393; 544/400

(58) Field of Search 544/372, 374, 544/393, 400; 514/252.13, 254.01, 254.1, 255.03

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,339,087 B1 * 1/2002 Gong et al. 514/252.12

FOREIGN PATENT DOCUMENTS

EP	0 903 349 A2	3/1999	
JP	5-92921 A2	4/1993	
WO	98/27081	* 6/1998	
WO	WO 99/65874	12/1999	
WO	WO 00/35449	6/2000	
WO	WO 00/35451	6/2000	
WO	WO 00/35452	6/2000	
WO	WO 00/35453	6/2000	
WO	WO 00/35454	6/2000	

OTHER PUBLICATIONS

Heath et al. J. Clin. Invest. vol. 99, p. 178–184 (1997).*
Owen, Pulmonary Pharmacology & Therapeutics, vol. 14, p. 193–202 (2001).*

* cited by examiner

Primary Examiner—Richard L. Raymond
(74) *Attorney, Agent, or Firm*—Grant D. Green

(57) **ABSTRACT**

The invention provides compounds of Formula (I):

(I)



wherein: R^1–R^4, A, L, and X have any of the values defined in the specification that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use, and methods and intermediates useful for preparing them.

20 Claims, No Drawings

US006906072B1

(12) **United States Patent**
Yamamoto et al.

(10) **Patent No.: US 6,906,072 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **PIPERAZINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND**

(75) Inventors: **Noboru Yamamoto**, Ibaraki (JP); **Yuichi Suzuki**, Ibaraki (JP); **Manami Kimura**, Chiba (JP); **Tetsuhiro Nikkome**, Ibaraki (JP); **Yoichi Iimura**, Ibaraki (JP); **Tetsuyuki Teramoto**, Brookline, MA (US); **Yoshihisa Kaneda**, Ibaraki (JP); **Toshihiko Kaneko**, Ibaraki (JP); **Nobuyuki Kurusu**, Ibaraki (JP); **Daisuke Shinmyo**, Ibaraki (JP); **Yukie Yoshikawa**, Ibaraki (JP); **Shinji Hatakeyama**, Ibaraki (JP)

(73) Assignee: **Eisai Co., Ltd.**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/169,837**

(22) PCT Filed: **Jan. 18, 2001**

(86) PCT No.: **PCT/JP01/00288**

§ 371 (c)(1),
(2), (4) Date: **Jul. 10, 2002**

(87) PCT Pub. No.: **WO01/53258**

PCT Pub. Date: **Jul. 26, 2001**

(30) **Foreign Application Priority Data**

Jan. 20, 2000 (JP) 2000-012176

(51) **Int. Cl.**[7] **C07D 409/06**; A61K 31/496; A61P 25/00; A61P 25/04

(52) **U.S. Cl.** **514/252.13**; 544/379

(58) **Field of Search** 514/252.12, 252.13, 514/253.01, 253.02, 253.11, 254.02, 254.03, 254.04, 254.06, 254.07, 254.11, 255, 2.3; 544/359, 360, 363, 364, 367, 368, 369, 366, 370, 37, 376, 377, 379, 391, 392, 402

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,994,460	A *	2/1991	Dextraze et al.	514/252.14
5,231,105	A	7/1993	Shoji	514/325
5,281,601	A	1/1994	Cross	514/320
5,420,131	A	5/1995	Carceller et al.	514/253
6,117,875	A	9/2000	Shimazaki et al.	514/253.01
6,426,345	B1	7/2002	Shimazaki et al.	514/234.2

FOREIGN PATENT DOCUMENTS

EP	0 393 574	A2	10/1990
EP	393574	A	10/1990
EP	400661	A	12/1990
EP	0 400 661	A1	12/1990
EP	0 441 226	A1	8/1991
EP	441226	A	8/1991
EP	0 458 459	A2	11/1991
EP	458459	A	11/1991
FR	2670225	A	11/1992
FR	2676225		11/1992
GB	1305458	A	1/1973
GB	1305458		1/1973
JP	47-38984		12/1972
JP	47-38984	A	12/1972
JP	62-286980	A	12/1987
JP	62-286980	A2 *	12/1987
JP	62-286980		12/1987
JP	63-35562	A	2/1988
JP	63-35562		2/1988
JP	64-3182	A	1/1989
JP	64-3182		1/1989
JP	64-61468	A	3/1989
JP	64-61468		3/1989
JP	2-83375	A	3/1990
JP	2-83375		3/1990

(Continued)

OTHER PUBLICATIONS

Jain KK., Expert Opin Investig Drugs. Oct. 2000;9(10):2403–10, Medline abstract PMID: 11060815.*

Gilmore, J. et al, Ann. Report Med. Chem., vol. 30, 1995, p 51–60.*

(Continued)

Primary Examiner—Thomas McKenzie
(74) *Attorney, Agent, or Firm*—Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.

(I)



In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C_{3-14} on hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R^1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D^1, D^2, W^1 and W^2 are the same as or different from each other and each represents a single bond or an optionally substituted C_{1-6} alkylene chain.

16 Claims, 3 Drawing Sheets

US006906070B2

(12) **United States Patent**
Lam et al.

(10) **Patent No.: US 6,906,070 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **GUANIDINE MIMICS AS FACTOR XA INHIBITORS**

(75) Inventors: **Patrick Y. Lam**, Chadds Ford, PA (US); **Charles G. Clark**, Cherry Hill, NJ (US); **Celia Dominguez**, Westlake, CA (US); **John M. Fevig**, Lincoln University, PA (US); **Qi Han**, Wilmington, DE (US); **Renhua Li**, Wilmington, DE (US); **Donald J. P. Pinto**, Kennett Square, PA (US); **James R. Pruitt**, Landenberg, PA (US); **Mimi L. Quan**, Newark, DE (US)

(73) Assignee: **Bristol-Myers Squibb Pharma Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 677 days.

(21) Appl. No.: **09/924,381**

(22) Filed: **Aug. 8, 2001**

(65) **Prior Publication Data**

US 2002/0025963 A1 Feb. 28, 2002

Related U.S. Application Data

(62) Division of application No. 09/099,358, filed on Jun. 18, 1998, now Pat. No. 6,339,099.
(60) Provisional application No. 60/050,265, filed on Jun. 20, 1997.

(51) **Int. Cl.**[7] **A61K 31/4725**; C07D 401/04

(52) **U.S. Cl.** **514/248**; 514/249; 514/266.2; 514/266.23; 514/300; 514/310; 514/313; 514/314; 514/373; 514/379; 514/395; 514/405; 514/406; 544/237; 544/258; 544/259; 544/260; 544/284; 544/293; 546/122; 546/143; 546/159; 548/207; 548/241; 548/304.7; 548/306.1; 548/362.1; 548/364.1; 548/364.4

(58) **Field of Search** 514/266.2, 266.23, 514/266.4, 310, 313, 314, 379, 394, 395, 405, 406; 544/284, 293; 546/143, 159; 548/241, 304.7, 306.1, 356.1, 362.1, 364.1, 364.4

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,202,330	A	4/1993	Atwal et al.	514/274
5,317,103	A	5/1994	Baker et al.	544/367
5,342,851	A	8/1994	Sanfilippo et al.	514/370
5,463,071	A	10/1995	Himmelsbach et al.	548/251
5,616,601	A	4/1997	Khanna et al.	514/399
5,681,838	A	10/1997	Zoller et al.	514/307
5,707,998	A	1/1998	Takase et al.	514/259
5,932,576	A *	8/1999	Anantanarayan et al.	514/235.5
5,998,424	A *	12/1999	Galemmo et al.	514/269
6,020,357	A	2/2000	Pinto et al.	514/406
6,403,620	B1 *	6/2002	Galemmo et al.	514/359

FOREIGN PATENT DOCUMENTS

EP	234830	A	9/1987
EP	236902	A	9/1987
EP	513387	B	11/1992
EP	554829	A	8/1993
JP	4247081	A	9/1992
WO	WO 9402477	A	2/1994
WO	WO 9514683	A	6/1995
WO	WO 9518111	A	7/1995
WO	WO 9628427	A	9/1996
WO	WO 9640143	A	12/1996
WO	WO 9723212	A	7/1997
WO	WO 9732583	A	9/1997

OTHER PUBLICATIONS

Tidwell et al. "Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases", J. Med. Chem. (1978), 21(7), 613–623.

* cited by examiner

Primary Examiner—Richard L. Raymond
(74) *Attorney, Agent, or Firm*—David H. Vance; Jing S. Belfield

(57) **ABSTRACT**

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I:

I



or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

16 Claims, No Drawings

(12) **United States Patent**
Li et al.

(10) **Patent No.: US 6,906,069 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **LXR MODULATORS**

(75) Inventors: **Leping Li**, Burlingame, CA (US); **Julio C. Medina**, San Carlos, CA (US); **Bei Shan**, Redwood City, CA (US)

(73) Assignee: **Amgen Inc.**, Thousand Oaks, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/479,315**

(22) Filed: **Jan. 6, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/115,292, filed on Jan. 8, 1999.

(51) **Int. Cl.**[7] **A01N 43/58**

(52) **U.S. Cl.** **514/247**; 514/461; 514/277; 514/438; 514/439

(58) **Field of Search** 546/283.4; 514/336

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,204,002	A	5/1980	Hubele	424/309
5,439,915	A *	8/1995	Commons et al.	514/292
6,090,853	A *	7/2000	Wetterich et al.	514/623

FOREIGN PATENT DOCUMENTS

DE	25 15 113	10/1975	C07C/105/46
DE	26 25 227	12/1976	C07D/231/40
DE	26 25 242	12/1976	C07D/307/66
DE	44 37 999 A1	5/1996	C07C/233/23
DE	44 38 020 A1	5/1996	C07C/233/41
EP	0 012 428 A1	6/1980	C07C/125/08
EP	0 013 360 A2	7/1980	C07D/249/08
EP	0 019 745 A1	12/1980	A01N/37/22
EP	0 023 669 A1	2/1981	C07C/103/737
JP	6323822	2/1988	
JP	0756392	7/1995	
JP	07118215	7/1995	
WO	WO 94/21611	9/1994	C07D/213/75
WO	WO 97/31637	9/1997	A61K/31/495
WO	WO 9735838 A1 *	10/1997	C07C/233/58
WO	WO 99/06382	2/1999	C07D/295/10
WO	WO 99/40064	8/1999	C07C/311/46
WO	WO 99/44987	9/1999	C07C/279/12
WO	WO 00/26186	5/2000	C07D/207/14
WO	WO 00/54759	9/2000	A61K/31/00

OTHER PUBLICATIONS

Athelstan L.J. Beckwith, etal: "Tandem Radical Translocation and Homolytic Aromatic Substitution: a Convenient and Efficient Route to Oxindoles" *J. Chem. Soc. Chem. Commun.*; pp. 977–978; (1995).

Sylvie Le Blanc, etal: "New Access to Sprianc β–Lactams" *Tetrahedron Lett*; 33(15) pp. 1993–1996 (1992).

Masazumi Ikeda, etal "Photochemistry of 2–(*N*–Acyl–*N*–alkylamino)cyclohex–2–enones: Formation of Spiro–β–lactams" *Chem. Pharm. Bull*; 34(12) pp 4997–5004 (1986).

Masazumi Ikeda, etal "Photochemical Synthesis of Spiro–β–lactams" *J. Chem. Soc. Chem. Commun*; pp 758–759 (1984).

* cited by examiner

Primary Examiner—James O. Wilson
Assistant Examiner—Jason H. Johnsen
(74) *Attorney, Agent, or Firm*—Townsend and Townsend and Crew LLP

(57) **ABSTRACT**

The invention provides compounds, compositions and methods for modulating the effects of LXRα in a cell. The compounds and compositions are useful both as diagnostic indicators of LXRα function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.

24 Claims, No Drawings

(12) **United States Patent**
South et al.

(10) **Patent No.: US 6,906,068 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL 1,2,4 - TRIAZINONES USEFUL AS ANTICOAGULANTS**

(75) Inventors: **Michael S. South**, St. Louis, MO (US); **Ashton T. Hamme, II**, St. Louis, MO (US); **William L. Neumann**, St. Louis, MO (US); **Darin E. Jones**, Ballwin, MO (US)

(73) Assignee: **Pharmacia Corporation**, St. Louis, MO (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/009,447**

(22) PCT Filed: **May 17, 2000**

(86) PCT No.: **PCT/US00/09806**

§ 371 (c)(1),
(2), (4) Date: **Apr. 3, 2002**

(87) PCT Pub. No.: **WO00/69832**

PCT Pub. Date: **Nov. 23, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/134,794, filed on May 19, 1999.

(51) **Int. Cl.**[7] **C07D 253/065**; C07D 239/02; A61K 31/53; A61K 31/513; A61P 7/02

(52) **U.S. Cl.** **514/242**; 514/269; 514/231.5; 544/182; 544/317; 544/111

(58) **Field of Search** 544/182; 514/242

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,489,096	A	12/1984	Terao et al.
4,851,413	A	7/1989	Terao et al.
4,992,469	A	2/1991	Ozawa et al.
5,008,267	A	4/1991	Katakami et al.
5,304,658	A	4/1994	Terao et al.
5,441,960	A	8/1995	Bernstein et al.
5,656,645	A	8/1997	Tamura et al.
5,658,930	A	8/1997	Tamura et al.
5,668,289	A	9/1997	Sanderson et al.
5,741,819	A	4/1998	Illig et al.
5,792,779	A	8/1998	Sanderson et al.
5,861,380	A	1/1999	Gyorkos et al
5,866,573	A	2/1999	Sanderson et al.
5,869,487	A	2/1999	Coburn et al.
5,872,138	A	2/1999	Naylor-Olsen et al.
6,011,158	A	1/2000	Tamura et al.
6,037,356	A	3/2000	Lu et al.
6,180,627	B1	1/2001	Blagg et al.

FOREIGN PATENT DOCUMENTS

DE	198 51 421	A1	5/2000
EP	0 354 495	A1	2/1990
WO	WO 98/09987	A1	3/1998
WO	WO 99/48892	A1	9/1998
WO	WO 99/43660	A1	9/1999

OTHER PUBLICATIONS

Rauch et al., Ann. Intern. Med. 134(3): 224–238, 2001.*
Van Aken et al., clin. Appl. Thromb. Hemost., 7(3): 195–204, 2001.*
Coburn, C.A., "Small-molecule direct thrombine inhibitors 1997–2000." Expert Opinions on Therapeutic Patents, 2001, 721–738, vol. 11, No. 5.
XP-002182132—Darvas, et al., "Investigation of the Common Mechanism of Action of Antibacterial Compounds Containing .gamma.-pyridone-.beta.-carboxylic acid Structure by Principal Component." Arzneim.-Forsch., 1979, pp. 1334–1339, vol. 29, 9.
XP-002172033—Kohama, et al., "Preparation of Piperidinyloxyacetylaminobenzoylalanine Derivatives and Analogs as Antithrombotics." JP 07,233,148.
XP-002187583—Moerner, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357.
Patel, et al., "Directed Aminomethylation of 3-Hydroxy-3(1H)-pyridinones and 3-hycroxy-4(1H)-pyridinones. Synthesis of iso-Deferiprone." Tetrahedron, 1996, pp. 1835–1840, vol. 52, No. 5.
XP-002182410—Trecourt, et al., "First Synthesis of (+-)-harzianopyridone by Metalation of Polysubstituted O-pyridylcarbamates." J. Heterocycl. Chem., 1995, pp. 1117–1114, vol. 32, No. 4.
Tulinsky, et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93–100, vol. 64, No. 1.

* cited by examiner

Primary Examiner—Venkataraman Balasubramanian

(57) **ABSTRACT**

The invention relates to substituted polycyclic aryl and heteroaryl pyrimidinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

15 Claims, No Drawings

US006906067B2

(12) **United States Patent**
Moriarty et al.

(10) **Patent No.: US 6,906,067 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **N-HETEROCYCLIC INHIBITORS OF TNF-α EXPRESSION**

(75) Inventors: **Kevin Joseph Moriarty**, Norristown, PA (US); **Yvonne Shimshock**, Hillsborough, NJ (US); **Gulzar Ahmed**, Yardley, PA (US); **Junjun Wu**, Malden, MA (US); **James Wen**, Dayton, NJ (US); **Wei Li**, Acton, MA (US); **Shawn David Erickson**, Leonia, NJ (US); **Jeffrey John Letourneau**, East Windsor, NJ (US); **Edward McDonald**, Banstead (GB); **Katerina Leftheris**, Skillman, NJ (US); **Stephen T. Wrobleski**, Whitehouse Station, NJ (US); **Zahid Hussain**, Monmouth Junction, NJ (US); **Ian Henderson**, Hopewell, NJ (US); **Axel Metzger**, East Windsor, NJ (US); **John J. Baldwin**, Gwynedd Valley, PA (US); **Alaric J. Dyckman**, Lawrenceville, NJ (US)

(73) Assignees: **Bristol-Myers Squibb Company**, Princeton, NJ (US); **Pharmaceopeia, Inc.**, Cranbury, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/891,750**

(22) Filed: **Jun. 26, 2001**

(65) **Prior Publication Data**

US 2002/0137747 A1 Sep. 26, 2002

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/747,195, filed on Dec. 22, 2000.

(60) Provisional application No. 60/173,227, filed on Dec. 28, 1999.

(51) **Int. Cl.**[7] **C07D 251/40**; C07D 251/48; C07D 251/52; A61K 31/53; A61P 35/00

(52) **U.S. Cl.** 514/341; 544/197; 544/198; 544/208; 544/209; 544/213; 544/217; 544/218

(58) **Field of Search** 544/197, 198, 544/208, 209, 213, 217, 218, 194; 514/241

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,290,305	A *	12/1966	Schmitz et al.	260/249.5
3,590,042	A *	6/1971	Cyba	260/249.6
3,625,979	A *	12/1971	Heimberger	260/247.5 R
3,867,383	A *	2/1975	Winter et al.	260/249.6
4,617,390	A *	10/1986	Hoppe et al.	544/197
4,724,137	A	2/1988	Hoppe et al.	424/59
5,062,882	A *	11/1991	Newton et al.	544/211
5,346,691	A *	9/1994	Raspani	544/197
5,759,525	A *	6/1998	Raspani et al.	544/197
5,801,244	A *	9/1998	Raspani	544/197
5,840,893	A	11/1998	Bukrinsky et al.	544/329
6,150,360	A *	11/2000	Dacynet et al.	544/194
6,288,228	B1 *	9/2001	Henkin et al.	544/197

FOREIGN PATENT DOCUMENTS

EP	834507	4/1998
EP	969004	1/2000
WO	WO95/30642	11/1995
WO	WO98/24782	6/1998
WO	WO99/01442	1/1999

OTHER PUBLICATIONS

Graninger et al. Curr. Opin. Rheumatol. 13(3): 209–13, 2001.*
Fujiwara et al., Bioorganic & Medicinal Chemistry Letters, vol. 10, p. 1317–1320 (2000).
Raingeaud et al., Molecular And Cellular Biology, vol. 16, No. 3, p. 1247–1255 (Mar. 1996).
Henry et al., Drugs and the Future, vol. 24 (12), p. 1345–1354 (1999).
Bresnihan et al., Arthritis & Rheumantism, vol. 41, No. 12, p. 2196–2204 (Dec. 1998).
Moreland et al., Annals of Internal Medicine, vol. 130, No. 6, p. 478–486 (Mar. 1999).
Bundgaard, Advanced Drug Delivery Reviews, vol. 3, p. 39–65 (1989).
Sabituro et al., Current Medicinal Chemistry, vol. 6, p. 807–823 (1999).
Rankin et al., British Journal of Rheumatology, vol. 34, p. 334–342 (1995).
Kotlyarov et al., Nature Cell Biology, vol. 1, p. 94–97 (1999).
Bodor et al., Annual Reports In Medicinal Chemistry, vol. 22, p. 303–313 (1987).

* cited by examiner

Primary Examiner—Venkataraman Balasubramanian
(74) *Attorney, Agent, or Firm*—Joseph C. Wang; Anastasia P. Winslow

(57) **ABSTRACT**

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I:

I



Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

20 Claims, No Drawings

US006906066B2

(12) **United States Patent**
Ko et al.

(10) **Patent No.: US 6,906,066 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY**

(75) Inventors: **Soo S. Ko**, Hockessin, DE (US); **George V. Delucca**, Pennington, NJ (US); **John V. Duncia**, Newtown, PA (US); **Joseph B. Santella, III**, Springfield, PA (US); **Dean A. Wacker**, Yardley, PA (US); **Paul S. Watson**, Carrboro, NC (US); **Jeffrey G. Varnes**, Newtown, PA (US); **Wenqing Yao**, Kennett Square, PA (US)

(73) Assignee: **Bristol-Myers Squibb Pharma Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 43 days.

(21) Appl. No.: **10/465,191**

(22) Filed: **Jun. 19, 2003**

(65) **Prior Publication Data**

US 2004/0058960 A1 Mar. 25, 2004

Related U.S. Application Data

(60) Division of application No. 09/598,821, filed on Jun. 21, 2000, now Pat. No. 6,605,623, which is a continuation-in-part of application No. 09/465,286, filed on Dec. 17, 1999, now abandoned.

(60) Provisional application No. 60/112,717, filed on Dec. 18, 1998, and provisional application No. 60/161,243, filed on Oct. 22, 1999.

(51) **Int. Cl.**[7] **C07D 211/08**; A61K 31/44

(52) **U.S. Cl.** **514/237.2**; 514/326; 514/331; 544/129; 546/209; 546/210; 546/231

(58) **Field of Search** 546/209, 210, 546/231; 544/129; 514/237.2, 326, 331

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,993,897	A	7/1961	Shapiro et al.	260/249.9
3,988,294	A	10/1976	Hill	
5,001,134	A	3/1991	Ferrand et al.	
5,236,921	A	8/1993	Emonds-Alt et al.	
5,317,020	A	5/1994	Emonds-Alt et al.	
6,331,541	B1 *	12/2001	Ko et al.	514/237.2
6,444,686	B1 *	9/2002	Ko et al.	514/318
6,525,069	B1 *	2/2003	Ko et al.	514/316

FOREIGN PATENT DOCUMENTS

DE	2614189	10/1977	
EP	0293880	12/1988	
EP	90/15048	12/1990	
EP	94/27992	12/1994	
EP	0685463	12/1995	
EP	903349	3/1999	
EP	479601	12/1999	
EP	747357	1/2002	
JP	1261383	10/1989	
WO	WO 94/27991	12/1994	
WO	WO 95/07266	3/1995	
WO	WO 96/24587	8/1996	
WO	WO 97/03060	1/1997	
WO	WO 97/19060	5/1997	
WO	WO 97/24325	7/1997	
WO	WO 97/40007	10/1997	
WO	WO 01/98270	5/1999	
WO	WO 99/24442	5/1999	
WO	WO 99/40931	8/1999	
WO	WO 00/29377	5/2000	

OTHER PUBLICATIONS

Kemp, et al., "Latent Inhibitors—Part 9", *J. Chem. Soc., Perkin Trans2* , 1993, vol. 4, pp. 741–748.

Nor et al., J. Of Chem. Soc., *Chem Commun*, 1987, vol. 6, pp. 480–482.

Kim, et al., "Migration and proliferation of guinea pig and human airway epithelial cells in response to tachykinins", *Am. J. Physiol.*, 1995, vol. 269, pp. L119–L126, *Chem. Abstract No.* 123:133809.

Kraneveld, et al., "Airway hyperresponsiveness; first eosinophils and then neuropeptides", *Int. J.Immunopharmacoo.*, 1998, vol. 19, 9/10, pp. 517–527, *Chem Abstract No.* 129:107602.

* cited by examiner

Primary Examiner—Deepak Rao
(74) *Attorney, Agent, or Firm*—Mary VanAllen

(57) **ABSTRACT**

The present application describes modulators of CCR3 of formula (I):

(I)



or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

31 Claims, No Drawings

US006906065B2

(12) **United States Patent**
Thomas

(10) **Patent No.: US 6,906,065 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **4-AMINO-5-CYANO-2-ANILINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELL-CYCLE KINASES**

(75) Inventor: **Andrew Peter Thomas**, Macclesfield (GB)

(73) Assignee: **AstraZeneca AB**, Sodertalje (SE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 30 days.

(21) Appl. No.: **10/239,790**

(22) PCT Filed: **Mar. 23, 2001**

(86) PCT No.: **PCT/GB01/01264**

§ 371 (c)(1),
(2), (4) Date: **Sep. 25, 2002**

(87) PCT Pub. No.: **WO01/72717**

PCT Pub. Date: **Oct. 4, 2001**

(65) **Prior Publication Data**

US 2003/0087923 A1 May 8, 2003

(30) **Foreign Application Priority Data**

Mar. 28, 2000 (GB) 0007371

(51) **Int. Cl.**[7] **C07D 239/48**; A61K 31/505

(52) **U.S. Cl.** **514/235.8**; 514/275; 544/122; 544/323; 544/324

(58) **Field of Search** 544/122, 323, 544/324; 514/235.8, 275

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,983,608	A	1/1991	Effland et al.	514/216
5,516,775	A	5/1996	Zimmermann et al.	514/224.2
5,521,184	A	5/1996	Zimmermann	514/252
5,610,303	A	3/1997	Kimura et al.	544/326
5,739,143	A	4/1998	Adams et al.	514/275
5,959,041	A	1/1999	Liverton et al.	514/396
5,985,877	A	11/1999	Dionne et al.	514/250

FOREIGN PATENT DOCUMENTS

CA	2231765		9/1998
EP	0 135 472		3/1985
EP	0 363 002		4/1990
EP	0 379 806	B1	8/1990
EP	0 564 409	B1	10/1993
EP	0 945 443	A1	9/1999
WO	91/18887		12/1991
WO	92/20642		11/1992
WO	95/09847		4/1995
WO	95/09851		4/1995
WO	95/09852		4/1995
WO	95/09853		4/1995
WO	95/15952		6/1995
WO	96/05177		2/1996
WO	96/28427		9/1996
WO	96/33980		10/1996
WO	96/40143		12/1996
WO	97/19065		5/1997
WO	97/35856		10/1997
WO	97/40017		10/1997
WO	97/44328		11/1997
WO	97/47618		12/1997
WO	98/11095		3/1998
WO	98/16230		4/1998
WO	98/18782		5/1998
WO	98/25619		6/1998
WO	98/33798	A	8/1998
WO	98/41512		9/1998
WO	98/54093		12/1998
WO	98/56788		12/1998
WO	99/01136		1/1999
WO	99/32121		1/1999
WO	99/18096		4/1999
WO	99/18942		4/1999
WO	99/31073		6/1999
WO	99/41253		8/1999
WO	99/50250		10/1999
WO	99/50251		10/1999

(Continued)

OTHER PUBLICATIONS

Traxler, Protein tyrosine kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6): 571–588, 1997.*

Bennett, Cecil Textbook of Medicine, 20th Ed., vol. 1, 1997, pp. 1004–1010.

(Continued)

Primary Examiner—Deepak Rao
(74) *Attorney, Agent, or Firm*—Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

Compounds of formula (I) wherein: R^1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl; p is 0–4; wherein the values of R^1 may be the same or different; R^2 is sulphamoyl or a group B-E- ; wherein B is optionally substituted as defined within and is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{3-6}alkyl, phenyl, a heterocyclic group, phenylC_{1-6}alkyl or (heterocyclic group)C_{1-6}alkyl; E is C(O)—, $N(R^a)C(O)$—, —$C(O)N(R^a)$—, —S(O),—, —$SO_2N(R^a)$— or —$N(R^a)SO_2$—; wherein R^a is hydrogen or C_{1-6}alkyl optionally substituted as defined within and r is 1–2; q is 0–2; wherein the values of R^2 may be the same or different; and wherein p+q=1–5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof are described. Processes for their manufacture and their use as inhibitors of cell cycle kinases, particularly CDK2, CDK4 and/or CDK6 are also described

(I)



11 Claims, No Drawings

(12) **United States Patent**
Scarborough et al.

(10) **Patent No.: US 6,906,063 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **PLATELET ADP RECEPTOR INHIBITORS**

(75) Inventors: **Robert M. Scarborough**, Half Moon Bay, CA (US); **Wolin Huang**, Foster City, CA (US); **Charles K. Marlowe**, Redwood City, CA (US); **Kim A. Kane-MaGuire**, Belmont, CA (US)

(73) Assignee: **Portola Pharmaceuticals, Inc.**, So. San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 318 days.

(21) Appl. No.: **09/920,325**

(22) Filed: **Aug. 2, 2001**

(65) **Prior Publication Data**

US 2002/0077486 A1 Jun. 20, 2002

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/775,812, filed on Feb. 5, 2001, now abandoned, and a continuation-in-part of application No. PCT/US01/03585, filed on Feb. 5, 2001.

(60) Provisional application No. 60/230,447, filed on Sep. 6, 2000, provisional application No. 60/202,072, filed on May 5, 2000, and provisional application No. 60/180,208, filed on Feb. 4, 2000.

(51) **Int. Cl.**[7] **C07D 417/12**; C07D 411/12; C07D 417/14; C07D 401/04; A61K 31/40

(52) **U.S. Cl.** 514/222.8; 514/231.5; 514/292; 514/293; 514/309; 544/9; 544/125; 544/126; 546/81; 546/82; 546/83; 546/141; 546/142

(58) **Field of Search** 514/222.8, 231.5, 514/292, 293, 309; 544/9, 125, 126; 546/81, 82, 83, 141, 142

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,847,925	A	11/1974	Beregi et al.	260/293.73
5,475,025	A	12/1995	Tjoeng et al.	514/466

FOREIGN PATENT DOCUMENTS

WO	WO 94/19341	9/1994	C07D/401/12
WO	WO 94/21602	9/1994	C07C/Z79/12
WO	WO 99/36425 A1	7/1999	
WO	WO 99/36425	7/1999	C07D/513/04
WO	WO 01/57057 A1	8/2001	

OTHER PUBLICATIONS

Plotnikova et al., "Arenesulfonamides. LXXX. Aroylarenesulfonamides". Database CA Online! Chemical Abstracts Service, Columbus, OH, US, retrieved from STN Database Accession No. 82: 139564 XP002215531, abstract, & *Vopr. Khim. Khim Tekhnol.* (1974), 33, 20–5.

Primary Examiner—Bruck Kifle
(74) *Attorney, Agent, or Firm*—Townsend and Townsend and Crew LLP

(57) **ABSTRACT**

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

8 Claims, No Drawings

(12) **United States Patent**
Chhabada et al.

(10) **Patent No.: US 6,906,062 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **CRYSTALLINE FORM I OF 2-METHYL-4-(4-MENTHYL-1-PIPERAZINYL) 10H THIENO [2,3-B][1,5]BENZODIAZEPINE**

(75) Inventors: **Vijay Chhangamal Chhabada**, Baroda (IN); **Rajeev Budhdev Rehani**, Baroda (IN); **Rajamamannar Thennati**, Baroda (IN)

(73) Assignee: **Sun Pharmaceutical Industries Limited**, Maharashtra (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/326,397**

(22) Filed: **Dec. 23, 2002**

(65) **Prior Publication Data**

US 2003/0125322 A1 Jul. 3, 2003

(30) **Foreign Application Priority Data**

Dec. 24, 2001 (IN) 1211/2001

(51) **Int. Cl.**[7] **A61P 25/18**; A61K 31/55; C07D 495/04

(52) **U.S. Cl.** **514/220**; 540/557

(58) **Field of Search** 514/220; 540/557

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,229,382 A 7/1993 Chakrabarti et al. 514/220
5,637,584 A * 6/1997 Larsen 514/220
5,703,232 A 12/1997 Bunnell et al. 540/557
5,736,541 A 4/1998 Bunnell et al. 514/220

FOREIGN PATENT DOCUMENTS

WO	WO 98/12199	3/1998
WO	WO 99 16312	4/1999
WO	WO 01 47933	7/2001

* cited by examiner

Primary Examiner—Brenda Coleman
(74) *Attorney, Agent, or Firm*—Westerman, Hattori Daniels & Adrian LLP

(57) **ABSTRACT**

Crystalline Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine characterised by x-ray powder diffraction peaks at approximately 9.94, 8.53, 8.19, 6.86, 6.35, 5.47, 4.83, 4.71, 4.53, 4.22, 4.08, 3.82, 3.75, 3.69, 3.50, 3.34, 3.11, 2.94, 2.82, 2.76, 2.59, 2.34, 2.03, 1.92 d (interplanar spacing) values; infrared absorbance bands at approximately 1456, 1365, 905, 757, 662 & 604 cm^{-3} and having stable colour at ambient conditions of storage; and the process of its preparation comprising at least two repetitive steps of crystallization from one or more organic solvent by dissolving 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine in said solvent and allowing crystallization to occur; wherein in at least one step the solution is purified by treating with a solid adsorbent material and filtering; and wherein in the last step the crystalline material is subjected to drying.

19 Claims, No Drawings


US006906061B2

(12) **United States Patent**
Uehata et al.

(10) **Patent No.: US 6,906,061 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **PHARMACEUTICAL AGENT CONTAINING RHO KINASE INHIBITOR**

(75) Inventors: **Masayoshi Uehata**, Iruma (JP); **Takashi Ono**, Iruma (JP); **Hiroyuki Satoh**, Chikujo-gun (JP); **Keiji Yamagami**, Iruma (JP); **Toshio Kawahara**, Chikujo-gun (JP)

(73) Assignee: **Mitsubishi Pharma Corporation**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/208,100**

(22) Filed: **Jul. 31, 2002**

(65) **Prior Publication Data**

US 2003/0134775 A1 Jul. 17, 2003

Related U.S. Application Data

(62) Division of application No. 09/791,648, filed on Feb. 26, 2001, now Pat. No. 6,451,825, which is a division of application No. 09/242,261, filed as application No. PCT/JP97/02793 on Aug. 8, 1997, now Pat. No. 6,218,410.

(30) **Foreign Application Priority Data**

Aug. 12, 1996 (JP) 8-212409

(51) **Int. Cl.**[7] **A61K 31/47**; C07D 401/12

(52) **U.S. Cl.** **514/218**; 514/309; 540/575; 546/139

(58) **Field of Search** 514/218, 309; 540/575; 546/139

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,478,836	A	12/1995	Arito et al.	514/300
6,218,410	B1	4/2001	Uehata et al.	514/352

FOREIGN PATENT DOCUMENTS

EP	0 061 673 A1	10/1982	
EP	0 187 371 A2	7/1986	
EP	0 654 266	5/1995	
EP	0 757 038 A1	2/1997	
EP	956865 *	11/1999	A61K/45/00
JP	62-89679	4/1987	
JP	3-218356	9/1991	
JP	5-273821	9/1992	
JP	5-194401	8/1993	

OTHER PUBLICATIONS

CPI English Abstract AN87-153220/22 of JP, 62-89679, A.
CPI English Abstract AN91-328389/45 of JP, 3-218356, A.
CPI English Abstract AN86-184348/29 of EP-187371-A (corresponding patent of JP, 61-227581, A).
CPI English Abstract AN90-357445/48 of JP, 2-256617, A.
CPI English Abstract AN92-361902/44 of JP, 2-264030, A.
CPI English Abstract AN94-065376/08 of WO94/03171 (corresponding patent of JP, 6-56668, A).
CPI English Abstract AN94-100832/12 of WO94/05290 (corresponding patent of JP, 6-80569, A).
CPI English abstract AN95-009548/02 of JP, 6-293643, A.
CPI English abstract AN95-118658/16 of JP, 7-41424, A.
CPI English abstract AN96-003284/01 of JP, 7-277979, A.
K. Jalink, et al., The Journal of Cell Biology, vol. 126, No. 3, pp. 801-810, 1994.
D. Leonard et al., The Journal of Biological Chemistry, vol. 267, No. 32, pp. 22860-22868, 1992.
S. Toratani, et al., FEBS Letters, vol. 324, No. 3, pp. 353-357, 1993.
H. Hidaka et al., Annu. Rev. Pharmacol. Toxicol., vol. 32, pp. 377-397, 1992.

* cited by examiner

Primary Examiner—Zinna Northington Davis
(74) *Attorney, Agent, or Firm*—Wonderoth, Lind & Ponack, L.L.P.

(57) **ABSTRACT**

A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug. In addition, the Rho kinase inhibitor is provided as a reagent and a diagnostic.

10 Claims, No Drawings

(12) **United States Patent**
Peschke et al.

(10) **Patent No.: US 6,906,060 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **SUBSTITUTED HEXAHYDROPYRROLO[1,2-A]PYRAZINES, OCTAHYDROPYRIDO[1,2-A]-PYRAZINES AND DECAHYDROPYRAZINO [1,2-A]AZEPINES**

(75) Inventors: **Bernd Peschke**, Malov (DK); **Rolf Hohlweg**, Kvistgaard (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 149 days.

(21) Appl. No.: **10/453,106**

(22) Filed: **Jun. 3, 2003**

(65) **Prior Publication Data**

US 2004/0023946 A1 Feb. 5, 2004

Related U.S. Application Data

(60) Provisional application No. 60/387,047, filed on Jun. 7, 2002.

(30) **Foreign Application Priority Data**

Jun. 6, 2002 (DK) 2002 00863

(51) **Int. Cl.**[7] **A01N 43/00**; A01N 43/58; A61K 31/55; C07D 487/00; C07D 401/00

(52) **U.S. Cl.** **514/214.02**; 514/249; 540/579; 544/238; 544/349

(58) **Field of Search** 514/214.02, 249; 540/579; 544/238, 349

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,164,598	A	1/1965	Freed	260/268
3,388,128	A	6/1968	Day et al.	260/268
6,316,475	B1	11/2001	Bennani et al.	514/343

FOREIGN PATENT DOCUMENTS

DE	2029185	12/1971	
DE	2141454	3/1972	
WO	WO 01/66534 A2	9/2001	
WO	WO 01/74810 A2	10/2001	

OTHER PUBLICATIONS

Alguacil and Perez-Garcia, "Histamine H3 Receptor: A potential Drug Target for the Treatment of Central Nervous System Disorders" Current Drug Targets—CNS & Neurological Disorders, vol. 2(5), pp. 303–313 (Oct. 2003).*

Leurs et al, "Therapeutic potential of histamine H3 receptor agonists and antagonists" Trends in Pharmacological Sciences, vo 19(5), pp. 177–183 (May 1998).*

Linney et al., Journal of Medicinal Chemistry, vol. 43, pp. 2363–2370 (2000).

DeCosta et al., Journal of Medicinal Chemistry, vol. 36, pp. 2311–2320 (1993).

Bromidge et al., Bioorganic and Medicinal Chemistry Letters, vol. 12: pp. 1357–1360 (2002).

* cited by examiner

Primary Examiner—Richard L. Raymond
Assistant Examiner—Zachary C. Tucker
(74) *Attorney, Agent, or Firm*—Rosemarie R. Wilk-Orescan; Reza Green; Richard W. Bork

(57) **ABSTRACT**

Novel substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino [1,2-a]azepines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

16 Claims, No Drawings

(12) **United States Patent**
Starke et al.

(10) **Patent No.: US 6,906,058 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS**

(75) Inventors: **Ingemar Starke**, Mölndal (SE); **Mickael Dahlström**, Mölndal (SE); **David Blomberg**, Mölndal (SE)

(73) Assignee: **AstraZeneca AB**, Södertälje (SE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/220,877**

(22) PCT Filed: **Mar. 5, 2001**

(86) PCT No.: **PCT/GB01/00909**

§ 371 (c)(1),
(2), (4) Date: **Sep. 6, 2002**

(87) PCT Pub. No.: **WO01/66533**

PCT Pub. Date: **Sep. 13, 2001**

(65) **Prior Publication Data**

US 2003/0166927 A1 Sep. 4, 2003

(30) **Foreign Application Priority Data**

Mar. 8, 2000 (SE) 0000772

(51) **Int. Cl.**[7] **C07D 281/10**; C07D 401/12; A61K 31/554; A61K 31/662; A61P 3/06

(52) **U.S. Cl.** **514/211.1**; 540/552

(58) **Field of Search** 540/552; 514/211.1

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

DE	19825804	12/1999
EP	0 864 582	9/1998
WO	93/16055	8/1993
WO	94/18183	8/1994
WO	94/18184	8/1994
WO	96/05188	2/1996
WO	96/08484	3/1996
WO	96/16051 A	5/1996
WO	97/33882	9/1997
WO	98/38182	9/1998
WO	98/40375	9/1998
WO	99/34278	7/1999
WO	99/35135 A	7/1999
WO	99/64409	12/1999
WO	99/64410	12/1999
WO	00/01687	1/2000
WO	00/38725	7/2000
WO	00/38726	7/2000
WO	00/38727	7/2000
WO	00/38728	7/2000
WO	00/38729	7/2000
WO	00/47568	8/2000
WO	00/61568	10/2000
WO	00/62810	10/2000
WO	01/60807 A1	8/2001
WO	01/68096 A2	9/2001
WO	01/68637 A2	9/2001
WO	02/08211 A2	1/2002
WO	02/32428 A2	4/2002
WO	02/50051 A1	6/2002
WO	03/020710 A1	3/2003
WO	03/022286 A1	3/2003
WO	03/022825 A1	3/2003
WO	03/022830 A1	3/2003

Primary Examiner—Bruck Kifle
(74) *Attorney, Agent, or Firm*—Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

The present invention relates to compounds of formula (I) wherein R^1 and R^3 are independently selected from C_{1-6}alkyl; one of R^4 and R^5 is a group of formula (IA): R^2, R^6, R^7, R^8, R^9, R^{10} and R^{11} and the other of R^4 and R^5 are as defined within, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and there use as ileal bile acid transport (IBAT) inhibitors for the treatment of hypolipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

12 Claims, No Drawings

US006906057B1

(12) **United States Patent**
Forman et al.

(10) **Patent No.: US 6,906,057 B1**
(45) **Date of Patent: Jun. 14, 2005**

(54) **METHODS FOR MODULATING FXR RECEPTOR ACTIVITY**

(75) Inventors: **Barry M. Forman**, Newport Beach, CA (US); **Richard L. Beard**, Newport Beach, CA (US); **Roshantha A. Chandraratna**, Laguna Hills, CA (US)

(73) Assignees: **Allergan, Inc.**, Irvine, CA (US); **City of Hope National Medical Center**, Duarte, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 422 days.

(21) Appl. No.: **09/590,447**

(22) Filed: **Jun. 9, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/138,968, filed on Jun. 11, 1999.

(51) **Int. Cl.**[7] **A61K 31/551**; A61K 31/553; A61K 31/554; A61K 31/55

(52) **U.S. Cl.** **514/211.08**; 514/211.15; 514/217.05; 514/218

(58) **Field of Search** 514/211.08, 211.15, 514/217.05, 218

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,053,523	A	10/1991	Chandraratna
5,278,318	A	1/1994	Chandraratna
5,324,744	A	6/1994	Chandraratna
5,346,895	A	9/1994	Chandraratna
5,348,972	A	9/1994	Chandraratna
5,348,975	A	9/1994	Chandraratna
5,407,937	A	4/1995	Chandraratna
5,663,347	A	9/1997	Chandraratna
5,776,699	A	7/1998	Klein et al.
5,808,083	A	9/1998	Johnson et al.
5,877,207	A	3/1999	Klein et al.

FOREIGN PATENT DOCUMENTS

WO	WO 00/40965	7/2000

OTHER PUBLICATIONS

Evans et al, "The Steroid and Thyroid Hormone Receptor Superfamily" Science vol. 240: 889–895 (May 1988).

Mangelsdorf et al, The Retinoid Receptors in The Retinoids: Biology, Chemistry, and Medicine Ch.8 (Sporn et al, eds. 2d ed, Raven Press Ltd. 1994).

Nagpal et al, "Retinoids as Anti–Cancer Agents", Current Pharm. Design 2:295–316 (1996).

Foreman et al, "Identification of a Nuclear Receptor That is Activated by Farnesol Metabolites", Cell vol. 81: 687–693 (1995).

Meigs et al, "Regulation of 3–Hydroxy–3–methylglutaryl–Coenzyme A Reductase Degradation by the Nonsterol Mevalonate Metabolite Farnesol in Vivo*", J. Biol. Chem. vol. 271: 7916–7922 (1996).

Chiang, "Regulation of Bile Acid Synthesis", Front. Biosci. 3: d176–193 (Feb. 1998).

Wang et al, "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", Molecular Cell vol. 3: 543–553 (May 1999).

Seed, "An LFA–3 cDNA encodes a phospholipid–linked membrane protein homologuous to its receptor CD2", Nature vol. 329: 840–842 (Oct. 1987).

(Continued)

Primary Examiner—San-ming Hui
(74) *Attorney, Agent, or Firm*—Hamilton, Brook, Smith & Reynolds, P.C.

(57) **ABSTRACT**

Methods for modulating the activity of the mammalian FXR receptor. The methods include methods of treating a hyper- or hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds having FXR receptor activity.

30 Claims, 9 Drawing Sheets



(12) **United States Patent**
Thompson et al.

(10) **Patent No.: US 6,906,056 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS**

(75) Inventors: **Richard C. Thompson**, Frankfort, IN (US); **Stephen Wilkie**, Indianapolis, IN (US); **Douglas R. Stack**, Fishers, IN (US); **Eldon E. Vanmeter**, Greenwood, IN (US); **Qing Shi**, Carmel, IN (US); **Thomas C. Britton**, Carmel, IN (US); **James E. Audia**, Indianapolis, IN (US); **Jon K. Reel**, Carmel, IN (US); **Thomas E. Mabry**, Indianapolis, IN (US); **Bruce A. Dressman**, Indianapolis, IN (US); **Cynthia L. Cwi**, Indianapolis, IN (US); **Steven S. Henry**, New Palestine, IN (US); **Stacey L. McDaniel**, Martinsville, IN (US); **Russell D. Stucky**, Indianapolis, IN (US); **Warren J. Porter**, Indianapolis, IN (US)

(73) Assignees: **Elan Pharmaceuticals, Inc.**, South San Francisco, CA (US); **Eli Lilly & Company**, Indianapolis, IN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/392,332**

(22) Filed: **Mar. 20, 2003**

(65) **Prior Publication Data**

US 2004/0106598 A1 Jun. 3, 2004

Related U.S. Application Data

(62) Division of application No. 09/338,191, filed on Jun. 22, 1999, now Pat. No. 6,569,851.
(60) Provisional application No. 60/160,067, filed on Jun. 22, 1998.

(51) Int. Cl.[7] **C07D 267/02**; C07D 487/00; C07D 223/12; A61K 31/55; A61P 25/28

(52) U.S. Cl. **514/211.06**; 514/212.03; 514/212.04; 514/212.07; 540/491; 540/522; 540/523; 540/527

(58) Field of Search 540/491, 522, 540/523, 527; 514/211.06, 212.04, 212.07, 212.03

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,598,859	A	8/1971	Yates et al.
3,657,341	A	4/1972	Thorne
4,080,449	A	3/1978	Croisier et al.
4,410,520	A	10/1983	Watthey
4,473,575	A	9/1984	Watthey
4,477,464	A	10/1984	Slade et al.
4,666,829	A	5/1987	Glenner et al.
4,977,168	A	12/1990	Bamat et al.
5,015,639	A	5/1991	Berger et al.
5,206,235	A	4/1993	Fisher et al.
5,238,932	A	8/1993	Flynn et al.
5,247,080	A	9/1993	Berger et al.
5,283,241	A	2/1994	Bochis et al.
5,284,841	A	2/1994	Chu et al.
5,324,726	A	6/1994	Dock et al.
5,360,802	A	11/1994	Chambers et al.
5,420,271	A	5/1995	Warshawsky et al.
5,478,857	A	12/1995	Clemens et al.
5,486,541	A	1/1996	Sterling et al.
5,502,048	A	3/1996	Chapdelaine et al.
5,519,061	A	5/1996	Youdim et al.
5,532,415	A	7/1996	Youdim et al.
5,556,969	A	9/1996	Chambers et al.
5,633,251	A	5/1997	Claremon et al.
5,656,626	A	8/1997	Chapdelaine et al.
5,658,901	A	8/1997	Claremon et al.
5,672,598	A	9/1997	De et al.
5,712,397	A	1/1998	Esser et al.
5,770,573	A	6/1998	Arrhenius et al.

FOREIGN PATENT DOCUMENTS

EP	0061187	9/1982
EP	0167919	1/1986

(Continued)

OTHER PUBLICATIONS

Aquino, et al. Discovery of 1,5–Benzodiazepines with Peripheral Cholecystokinin (CCK–A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." *J. Med. Chem.* 39: 562–569 (1996).

Blade–Font. "Facile Synthesis of γ–,5–, and γ–lactams by Cyclodehydration of ω–amino Acids on Alumina or Silica Gel." *Tetrahedron Letters* 21: 2443–2446 (1980).

Bock, et al. "Synthesis and Resolution of 3–Amino–1, 3–dihydro–5–phenyl–2H–1,4–benzodiazepin–2–ones." *J. Org. Chem.* 52: 3232–3239 (1987).

Bock, et al. "An Expedient Synthesis of 3–Amino–1, 3–Dihydro–5–Phenyl–2H–1,4–Benzodiazepin–2–one." *Tet. Lets.* 28(9): 939–942 (1987).

Bock, et al. "Selective Non–Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." *Bioorg. and Med. Chem. Lets.* 2(9):987–998 (1994).

(Continued)

Primary Examiner—Bruck Kifle
(74) *Attorney, Agent, or Firm*—Burns, Doane, Swecker & Mathis, LLP

(57) **ABSTRACT**

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

48 Claims, No Drawings

US006906054B2

(12) **United States Patent**
Buynak et al.

(10) **Patent No.: US 6,906,054 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **COMPOSITIONS FOR INHIBITING BETA-LACTAMASE**

(75) Inventors: **John D. Buynak**, Dallas, TX (US); **A. Srinivasa Rao**, Waukegan, IL (US); **Greg C. Adam**, Dallas, TX (US); **Sirishkumar D. Nidamarthy**, Devon, PA (US); **Venkata Ramana Doppalapudi**, Dallas, TX (US)

(73) Assignee: **Research Corporation Technologies, Inc.**, Tucson, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 12 days.

(21) Appl. No.: **10/143,636**

(22) Filed: **May 10, 2002**

(65) **Prior Publication Data**

US 2003/0036541 A1 Feb. 20, 2003

Related U.S. Application Data

(62) Division of application No. 09/548,209, filed on Apr. 13, 2000, now Pat. No. 6,407,091.

(60) Provisional application No. 60/129,482, filed on Apr. 15, 1999.

(51) **Int. Cl.**[7] **A61K 31/545**

(52) **U.S. Cl.** **514/200**; 514/201; 514/202; 514/208; 514/209

(58) **Field of Search** 514/200, 201, 514/202, 208, 209, 224.2

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,053,468	A	10/1977	Holden	544/30
4,150,156	A	4/1979	Beattie et al.	424/246
4,356,174	A	10/1982	Barth	424/114
4,456,755	A	6/1984	Sheehan et al.	544/23
4,459,405	A	7/1984	Hall	544/28
4,512,999	A	4/1985	Adam Molina et al.	514/192
4,547,371	A	10/1985	Doherty et al.	514/200
4,559,157	A	12/1985	Smith et al.	252/90
4,608,392	A	8/1986	Jacquet et al.	514/844
4,637,999	A	1/1987	Doherty et al.	514/201
4,820,508	A	4/1989	Wortzman	424/59
4,826,833	A	5/1989	Chen	514/192
4,861,768	A	8/1989	Tuzii et al.	514/195
4,912,213	A	3/1990	Taniguchi et al.	540/310
4,938,949	A	7/1990	Borch et al.	424/10
4,992,478	A	2/1991	Geria	514/782
4,992,541	A	2/1991	Blacklock et al.	540/221
5,077,286	A	12/1991	Bissolino et al.	514/201
5,126,446	A	6/1992	Brown, Jr. et al.	540/230
5,258,377	A	11/1993	Maiti et al.	540/221
5,264,429	A	11/1993	Maiti et al.	514/202
5,348,952	A	9/1994	Bissolino et al.	514/202
5,356,888	A	10/1994	Alpegiani et al.	514/204
5,364,848	A	11/1994	Doherty et al.	514/201
5,446,037	A	8/1995	Maiti et al.	514/201
5,597,817	A	1/1997	Buynak et al.	514/200
5,629,306	A	5/1997	Buynak et al.	514/206
5,637,579	A	6/1997	Hubschwerlen et al.	514/192
5,658,567	A	8/1997	Calhoun et al.	424/94.61
5,681,563	A	10/1997	Buynak et al.	424/114
5,760,027	A	6/1998	Buynak et al.	514/200
6,156,745	A	12/2000	Buynak et al.	514/192
6,303,592	B1	10/2001	Buynak et al.	514/206
6,391,855	B1	5/2002	Blaschuk et al.	514/17

FOREIGN PATENT DOCUMENTS

DE	2708219	9/1977
EP	0041047	12/1981
EP	0041768	12/1981
EP	0050805	5/1982
EP	0120613	10/1984
EP	0150984	8/1985
EP	0170192	2/1986
EP	0210065	1/1987

(Continued)

OTHER PUBLICATIONS

Buynak, John.D. ,et al. ,"7-Alkylideneepbalosporin esters as Inhibitors of Human Leukocyte Elastase", *J. Med. Chem.*, vol. 40,(1997),pp. 3423-3433.

(Continued)

Primary Examiner—Phyllis G. Spivack
(74) *Attorney, Agent, or Firm*—Schwegman, Lundberg, Woessner & Kluth, P.A.

(57) **ABSTRACT**

The invention provides pharmaceutical compositions comprising compounds of formula I and IV:

I



IV



wherein R_2-R_{11} and A have any of the values defined in the specification, and their pharmaceutically acceptable salts. The pharmaceutical compositions are useful for inhibiting β-lactamase enzymes, for enhancing the activity of β-lactam antibiotics, and for treating β-lactam resistant bacterial infections in a mammal.

12 Claims, 4 Drawing Sheets

US006906053B2

(12) **United States Patent**
Sheppeck et al.

(10) **Patent No.: US 6,906,053 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **HYDANTOINS AND RELATED HETEROCYCLES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)**

(75) Inventors: **James E. Sheppeck**, Willington, DE (US); **Jingwu Duan**, Newark, DE (US); **Chu-Biao Xue**, Hockessin, DE (US); **Zelda Wasserman**, Wilmington, DE (US)

(73) Assignee: **Bristol-Myers Squibb Pharma Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/844,219**

(22) Filed: **May 12, 2004**

(65) **Prior Publication Data**

US 2004/0209874 A1 Oct. 21, 2004

Related U.S. Application Data

(62) Division of application No. 10/155,575, filed on May 23, 2002, now Pat. No. 6,890,915.
(60) Provisional application No. 60/293,571, filed on May 25, 2001.

(51) Int. Cl.[7] **A61K 31/33**; C07D 487/00; C07D 233/00; C07D 221/00; C07D 215/00

(52) U.S. Cl. **514/183**; 514/311; 514/385; 514/396; 514/399; 514/409; 514/412; 514/422; 514/425; 548/300.1; 548/300.7; 548/407; 548/408; 548/409; 546/112; 546/134; 546/16

(58) Field of Search 514/183, 311, 514/385, 396, 399, 409, 412, 422, 425; 548/300.1, 407, 317.1, 409; 546/112, 134, 16

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,315,031	A	2/1982	Vincent et al.
4,816,454	A	3/1989	Zoller et al.
5,567,725	A	10/1996	Hemmerle et al.
5,811,459	A	9/1998	Breault et al.
5,821,241	A	10/1998	Claremon et al.
5,861,380	A	1/1999	Gyorkos et al.
6,048,877	A	4/2000	Ahmad et al.
6,268,379	B1	7/2001	Xue et al.

FOREIGN PATENT DOCUMENTS

CS	151744	11/1973
JP	5213957 *	8/1993
WO	WO 99/24416	5/1999
WO	WO 00/35886	6/2000
WO	WO 01/12189	2/2001
WO	WO 01/23363	4/2001
WO	WO 01/44217	6/2001
WO	WO 02/074748	9/2002
WO	WO 02/074749	9/2002
WO	WO 02/074750	9/2002
WO	WO 02/074751	9/2002
WO	WO 02/074752	9/2002
WO	WO 02/074767	9/2002

OTHER PUBLICATIONS

Chemical Abstract DN 120:271177, also cited as JP 5213957 dated Aug. 1993.*
Knabe et al., "Racemates and enantiomers of basic substituted 5-phynylhydantoins. Syntheses and antiarrhythmic activity," PHARMAZIE, vol. 52 No. 12, 1997, pp. 912–919.
Aharony et al., "Pharmacacological Characterization of a New Class of Non-Peptide Neurokinin A Antagonists that Demonstrate Species Selectivity", *J. Pharmacol. Exp. Ther.*, 1995, 274(3), pp. 1216–1221.
PubMed Abstract 145790524, also cited as *Curr. Opin. Drug Disc.*, 6/5, 2003, pp. 742–759.
PubMed Abstract 11934805, also cited as *Br. J. Pharmacol.*, 135/7, 2002, pp. 1655–1664.
PubMed Abstract 12082286, also cited as *Biorheology*, 39/1–2, 2002, pp. 237–246.
PubMed Abstract 14524529, also cited as *Clin. Exp. Metastasis*, 20/5, 2003 pp. 407–412.

* cited by examiner

Primary Examiner—Richard L. Raymond
Assistant Examiner—Sudhaker B. Patel
(74) *Attorney, Agent, or Firm*—Jing G. Sun

(57) **ABSTRACT**

The present application describes novel hydantoin derivatives of formula (I):

(I)



or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^{11}, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.

24 Claims, No Drawings

US006906051B2

(12) **United States Patent**
Ruminiski et al.

(10) **Patent No.: US 6,906,051 B2**
(45) **Date of Patent: Jun. 14, 2005**

(54) **LACTONE INTEGRIN ANTAGONISTS**

(75) Inventors: **Peter Ruminiski**, Ballwin, MO (US); **Thomas D. Penning**, Elmhurst, IL (US); **Lan Jiang**, Ballwin, MO (US); **Balekudru Devadas**, Chesterfield, MO (US); **Thomas Rogers**, Ballwin, MO (US); **Jennifer VanCamp**, Glencoe, MO (US); **Chester Yuan**, Souther Oaks, CA (US)

(73) Assignee: **Pharmacia Corporation**, St. Louis, MO (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/717,238**

(22) Filed: **Nov. 19, 2003**

(65) **Prior Publication Data**

US 2004/0116472 A1 Jun. 17, 2004

Related U.S. Application Data

(62) Division of application No. 09/963,926, filed on Sep. 26, 2001, now Pat. No. 6,720,327.

(60) Provisional application No. 60/241,633, filed on Oct. 19, 2000, and provisional application No. 60/235,617, filed on Sep. 27, 2000.

(51) **Int. Cl.**[7] **A61K 31/33**; A61K 31/505; C07D 239/00; C07D 407/00; C07D 305/00

(52) **U.S. Cl.** **514/183**; 514/514; 514/269; 514/256; 514/561; 514/482; 514/617; 514/473; 544/244; 544/297; 544/298; 544/322; 544/330; 544/335; 546/1; 549/263; 549/295; 549/321; 549/323

(58) **Field of Search** 514/183, 269, 514/256, 561, 482, 617, 449, 473; 544/224, 297, 298, 322, 330, 335; 546/1; 549/263, 295, 321, 323

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,602,155	A	2/1997	Ruminski	514/357
6,013,651	A	1/2000	Rogers et al.	514/269
6,028,223	A *	2/2000	Ruminski et al.	564/27
6,211,191	B1	4/2001	Duggan et al.	514/274
6,720,327	B2 *	4/2004	Ruminski et al.	514/269

FOREIGN PATENT DOCUMENTS

EP	0641800	1/1994	C07K/5/06
WO	9708145 *	3/1997	

OTHER PUBLICATIONS

U.S. Appl. No. 10/381,834, filed Aug. 23, 2003.*
Cecil Textbook of Medicine,20th Edition, vol. 1,1004–10(1996).*
Uckun et al, Current cancer Drug Targets,1/1,59–71(2001).*
PubMed 12082286,also cited as Biorheology,39/1–2, 251–46(2002).*
PubMed Abstract 12851778,also cited as Acta Neuropathol. (Berl) 106/4,319–22(2003).*
PubMed Abstract 12234368,also cited as Immunol. Rev. 186, 125–40(2002).*
PubMed Abstract 14718670, also cited as Proc. Natl. Acad. Sci.USA, 101/3,763–8(2004).*
PubMed Abstract 10723092, also cited as Cell Biochem. 77/2,265–76(2000).*
PubMed Abstract 12657612, also cited as Invest. Ophthalmol. Vis. Sci. 44/4,1704–15(2003).*
Carron, et al., *Cancer Research*; V. 58, No. 9: pp. 1930–1935; 1998.
Lark, et al., *Journal of Bone & Mineral Research*; V. 16, No. 2: pp. 319–327; 2000.
Healy, et al., *Human Reproductive Update*; V. 4: pp. 136; 1998.
Cheresh, *Cancer Metastasis Review*; V. 10: pp. 3–10; 1991.
Brooks, et al., *Cell*; V. 79, No. 7: pp. 1157–1164; 1994.
Friedlander, et al., *Proceedings Of The National Academy Of Science USA*; V. 93, No. 18; pp. 9764–9769; 1996.
Badger, et al., *Arthritis & Rheumatism*; V. 44, No. 1: pp. 128–137; 2001.
Brown, *Cardiovascular Research*; V. 28; pp. 1815–; 1994.
Friedlander, et al., *Science*; V. 270 (5241): pp. 1500–1502; 1995.
Agrez, et al., *Journal of Cell Biology*; V. 127, No. 2: pp. 547–556; 1994.
Christofidou–Solomidou, et al., *American Journal of Pathology*; V. 151 (4): pp. 975–983; 1997.
Seftor, et al., *Proceedings of the National Academy of Science USA*; V. 89: pp. 1557–1561;Mar. 1992.
Montgomery, et al., *Proceedings of the National Academy of Science USA*; V. 91: pp. 8856–8860; Sep. 1994.
Adamis, et al., *American Journal of Ophthalmology*; V. 118: pp. 445–450; 1994.

(Continued)

Primary Examiner—Richard L. Raymond
Assistant Examiner—Sudhaker B. Patel
(74) *Attorney, Agent, or Firm*—Harness, Dickey & Pierce, LLP

(57) **ABSTRACT**

The present invention relates to a class of compounds represented by the Formula I:

I



or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the $\alpha_v\beta_3$ and/or the $\alpha_v\beta_5$ integrin.

12 Claims, No Drawings